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Ischemic myocardial tissue will, inevitably, undergo necrosis if blood flow is not 
restored immediately. Early reperfusion after coronary obstruction is well established to 
recover injured myocardium; nevertheless reperfusion itself is believed to bring about 
additional cellular injury, termed as myocardial ischemia-reperfusion injury (or 
“reperfusion injury”).  
 
Since the 1980s, there are numerous studies working on the pathogenesis and therapy 
of myocardial ischemia and reperfusion (MI/R) injury. Nitric Oxide (NO)-donating 
compounds have shown promise as protective agents in experimental models of regional 
ischemia-reperfusion. In the present study, we applied the NO-slow-releasing derivatives 
of Nonsteroidal Anti-Inflammatory Drug (NO-NSAIDs, e.g. NO-Aspirin and NO-
Paracetamol) to investigate the cardioprotective effect of NO donor and the possible 
mechanism(s) involved. Moreover, another member of active endogenously generated 
gas, hydrogen sulfide (H2S), emerges to play a role in the cardiovascular system and 
reperfusion injury.  Thus, we also investigated the time course of H2S production and its 
possible role in the rat model of MI/R. The main findings of the present work are 
summarized as below: 
 
In the first experiment, we found that pre-treatment of NO-Aspirin significantly 
restored ischemia/reperfusion-induced myocardial contractile dysfunction, decreased 
infarct size and downregulated the iNOS mRNA expression and plasma nitrites and 
nitrates concentration compared with those of vehicle or aspirin-treated groups. These 
 xiii
beneficial effects of NO-Aspirin probably derive mainly from the NO moiety, which 
interferes with and modulates the iNOS-induced cellular damage. However, pre-
treatment with NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), aggravated 
myocardial damage in terms of mortality and infarct size. The data showed that sufficient 
NO availability during ischemia reperfusion could confer the cardioprotection.  
 
In the second experiment, we examined the time course of cystathionine γ-lyase (CSE, 
H2S producing enzyme in heart) mRNA expression and activity during the MI/R. The 
biphasic pattern of H2S production was observed: declined in the early reperfusion, but 
increased hours after I/R and reached the maximal around 24-48 hour. Furthermore, the 
role of H2S in the reperfusion-characterizing inflammation was studied by applying a 
CSE inhibitor (D, L--propargylglycine, PAG) and H2S donor (NaHS). The pro-
inflammatory effect of H2S was noted by NaHS-induced neutrophil infiltration, while 
PAG-offered cardioprotection via inhibiting H2S biosynthesis, then attenuating pro-
inflammatory cytokine-induced neutrophil infiltration. 
 
In the third experiment, we found that pre-treatment, but not post-treatment, with NO-
paracetamol exerted the cardioprotective effects, which is likely pre-treated-NO mediated 
attenuation of myocardial H2S production, pro-inflammatory cytokine levels and 
myeloperoxidase (MPO) activation. Sodium nitroprusside (SNP), as a NO donor control, 
exerted similar effects on the pro-inflammatory H2S production and neutrophil infiltration. 
 
These findings would support the notion that increased NO availability is a useful 
pharmacological intervention that limits tissue injury in MI/R. In addition, our results 
 xiv
suggest that H2S is likely to play a pro-inflammatory role in determining the severity of 
reperfusion injury in the rat model of MI/R. More importantly, we propose that the 
appropriate dose of NO/H2S donor or inhibitor should be administered at appropriate time 
of myocardial ischemia reperfusion. The new information regarding the roles of NO and 
H2S in myocardial ischemia-reperfusion could deepen our understanding of mechanisms 
of reperfusion injury and contribute to future therapeutic strategies that can attenuate the 
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1.1 General Overview 
 
Although impressive progress in the diagnosis and management of cardiovascular 
(CV) disease has been made in the past five decades, CV disease is still the leading cause 
of mortality and is responsible for 16.73 million deaths (29.3%) annually around the 
world (WHO, 2004). Furthermore, the 20th century has seen a dramatic increase in life 
expectancy in many developed countries and even in some developing countries. 
However, with the aging of the population, there has also been an exponential rise in the 
prevalence of CV disease (WHO, 2006). For example, of the 71,300,000 American adults 
with one or more types of cardiovascular (CV) disease, 27,400,000 are estimated to be at 
age 65 or above with more than 80% of CV deaths occurring in this age group (NHANES, 
1999–2002).  
Ischemic heart disease is the most common and severe form of CV disease. WHO 
estimated that in 2002, 12.6% of deaths worldwide were from ischemic heart disease 
(WHO, 2004) and approximately 50% of ischemic heart deaths were attributed to 
coronary heart disease (CHD) (Goldberg et al., 1999). In the U.S., coronary heart disease 
is responsible for 1 in 5 deaths. Some 7,200,000 men and 6,000,000 women are living 
with some form of coronary heart disease. 1,200,000 people suffer a (new or recurrent) 
coronary attack every year, and about 40% of them die as a result of the attack (AHA, 
2006). The therapeutic goal for coronary heart disease is thus to prompt the re-
establishment of coronary artery patency and the following early myocardial reperfusion.  
Currently, the main treatment protocols include thrombolytic therapy, percutaneous 
coronary intervention and coronary artery bypass surgery (CABS). However, these 
treatment protocols all require early reperfusion to reintroduce blood flow to the ischemic 
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myocardium (Braunwald, 2002).  Early reperfusion of an infarct-related artery of the 
heart is essential to prevent further ischemic injury to the myocardium; as such, it is 
central to the modern treatment of coronary heart events. However, the reintroduction of 
blood flow to the vulnerable but still viable myocardial tissue may potentially lead to 
accelerated and additional myocardial injury generated by ischemia alone involving both 
intracellular and extracellular mechanisms (Verma et al., 2002). The combined 
detrimental effects of myocardial ischemia and reperfusion are termed 
ischemia/reperfusion (I/R) injury (Yellon et al., 2000). Identification of the molecular 
triggers, cell signaling pathways and underlying mechanisms involved in myocardial I/R 
injury will lead to a better understanding of the progress of ischemia heart disease and 
thus allow for the development of new treatment strategies to reduce the incidence of 
coronary heart disease. 
 
1.2 Myocardial Ischemia-reperfusion Injury (MI/R) 
 
1.2.1   Overview of MI/R 
 
The myocardium can tolerate brief ischemia (up to 10-15 minutes) without leading to 
cardiomyocyte death. Although the cardiomyocytes do suffer injury as a result of the 
ischemic event, the damage is reversible with prompt reperfusion. With increasing 
duration and severity of ischemia, reperfusion may accelerate the development of 
necrosis in injured myocytes and a spectrum of reperfusion-associated pathologies, 
collectively termed reperfusion injury (Kloner et al., 2001a; Kloner et al., 2001b; Yellon 
et al., 2000). In the clinical setting, reperfusion injury after re-introduction of oxygenated 
blood flow is manifested by reperfusion arrhythmia, microvascular/endothelial 
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dysfunction including the no-reflow phenomenon, myocardial stunning and irreversible 
cell damage or necrosis (Maxwell et al., 1997; Moens et al., 2005; Opie, 1989; Vroom et 
al., 1996). Reperfusion arrhythmia and microvascular/endothelial dysfunction do not 
cause severe consequences for the clinician due to their low incidence and relative ease of 
treatment. Myocardial stunning is the best-established manifestation of reperfusion injury. 
This term  is explained by  “prolonged postischemic dysfunction of viable tissue salvaged 
by reperfusion (Braunwald, 1991; Cooper et al., 2001). The salvaged myocytes is capable 
of  restoring spontaneously contractile function requiring a prolonged period, ranging 
from a few hours to several days (Yellon et al., 2000; Kloner et al., 2001a; Kloner et al., 
2001b). Reperfusion of a severely ischemic myocardium may result in irreversible cell 
damage or necrosis, termed lethal reperfusion injury. Lethal reperfusion injury is defined 
as injury caused by restoration of blood flow after an ischemic episode leading to death 
of cells that were only reversibly injured during that preceding ischemic episode (Piper et 
al., 1998). 
The underlying pathophysiological mechanisms and mediators of reperfusion injury 
have not been fully elucidated. The most frequently cited include oxygen-derived free 
radicals (ODFR), neutrophil-mediated injury and intracellular calcium overload 
(Kaminski et al., 2002; Moens et al., 2005; Zweier et al., 2006). 
Currently, there are three possible ways that may influence this reperfusion injury: 
induction of pre- or post-conditioning and a pharmacological approach. Preconditioning 
can be induced by ischemia itself ( termed as “ischemic preconditioning”) before 
prolonged ischemia, or be induced by drugs, including adenosine, opioids and bradykinin 
β2-receptor agonist (Moens et al., 2005). Postconditioning was introduced by Vinten-
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Johansen’s group (Zhao et al., 2003b) by controlling the blood flow to ischemic 
myocardium in a stuttering fashion, which is also called “controlled reperfusion”. The 
pharmacological approach for preventing reperfusion injury is by administration of drugs, 
either systemically before reperfusion or by intra-coronary infusion at the onset of 
reperfusion, targeting oxygen-derived free radical (ODFR), leukocyte activation or blood 
components (i.e., calcium concentration, osmolality) (Ignarro, 2000).  
Nitric oxide (NO), as an active gaseous molecule, plays a pivotal role not only in its  
cardioprotective role in the pre- and post-conditioning (Bolli, 2001; Jones et al., 2006),  
but also in the progress of inflammation during reperfusion injury which represents one 
of the most widely studied yet controversial subjects in physiology (Liu et al., 1997; 
Grisham et al., 1999; Cuzzocrea et al., 2002). Therefore, there is a growing interest in 
studying the effects of NO in the myocardial ischemia-reperfusion. 
 
1.2.2   Regional rat MI/R model 
 
There are two models that are being utilized in myocardial ischemia–reperfusion 
study: 1) in vivo regional ischemia-reperfusion model in the anaesthetized animals; and 2) 
ex vivo isolated myocardial global ischemia – reperfusion. 
Regional ischemia-reperfusion model in the anaesthetized animals is well established 
and used in many laboratories (Ytrehus, 2000). Briefly, regional ischemia is introduced 
by ligating the coronary artery and then releasing the ligation after a period of ischemia to 
restore the blood supply to cardiac tissue that is perfused by the coronary arteries. This in 
vivo model offers the advantage of being a highly physiological preparation and is 
relevant to the clinical setting. In addition, it provides knowledge about infarct size 
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limitation as well as heart function in acute and chronic ischemia in a wide variety of 
species. However, the isolated heart model offers distinct advantages in assessing 
coronary vascular responses and continuous ventricular contractility devoid of whole 
body compensatory mechanisms such as nervous system and the involvement of blood 
cells. A comparison between the advantages and disadvantages of these two models is 
listed in Table 1.1. 
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Table 1.1. Advantages and disadvantages of I/R experimental models 
 




1. Most closely resemble the clinical 
situation 
2. A homogenous study population  
3. Standardization of regional ischemia 
is easy 
4.  Instrumentation can include 
catheters for blood samples, drug 
delivery and for blood pressure and 
left ventricular haemodynamic 
measurement 
5. Prolonged observation time for 
cardiac function, signaling pathway 
and pathophysiological tissue 
remodeling after ischemia in live 
animals 
6. Infarct size, arrhythmias and 





1. Stable preparation, easy to use  
2. Standardized conditions during 
reperfusion  
3. Global ischemia results in a 
homogenous tissue that enables 
the use of homogenized tissue 
for biochemical analyses  
4. Permits interventions both prior 
to removal of the heart and 
during the perfusion before or 
after ischemia  
5. Influence by the nervous system 
and blood-born cells upon 
outcome of ischemia is excluded 
 
Disadvantages   
 
Anesthetic agent will influence the outcome 
 
1. Maintain cellular homeostasis 
for a limited time and is prone to 
deterioration  
2. Conventional histology for 
ischemia-induced necrosis is not 
possible  
3. The perfusion solution lacks 
blood cells, plasma proteins, 
growth factors and this leads to 
changes in vascular function  
4. With the intraventricular balloon 
the papillary muscle is not 




Adapted from The ischemic heart--experimental models Pharmacol Res 2000:42(3), 193-
203 (Ytrehus, 2000) 
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1.3 Nitric Oxide (NO) 
 
1.3.1   Overview of NO 
 
NO is a heterodiatomic free radical gas occuring in nature. Moreover, NO appears to 
be one of the most ubiquitous substances in mammalian species and can participate in a 
wide range of biochemically relevant reactions to evoke profound biological responses in 
the body (Ignarro, 2000; Loscalzo et al., 2000).  
In the past, NO is seen as an atmospheric pollutant originating from the exhaust of 
motor engines and industrial processes. NO is also formed by the action of lightning 
(Levine et al., 1984) and is found in tobacco smoke (Vleeming et al., 2002).  
As early as the mid-19th century, organic nitrovasodilators ( a class of NO donors ) 
have drawn the attention of scientists and clinicians to their efficacy in patients suffering 
from angina pectoris.  Nevertheless, after more than a century,  scientists clearly ascribed 
the biological activity of such compounds to NO as an endogenous modulator of vascular 
tone by a cyclic  GMP-dependent mechanism (Furchgott et al., 1980; Ignarro, 1989; 
Palmer et al., 1987). The delay was due, in part, to the fact that it is hard to believe that a 
well-known pollutant could have such a physiological function.  
In the past three decades, NO became the interest of a significant number of 
investigators who pursued its molecular biology and physiological function in different 
fields of life sciences. The number of annual publications dealing with NO has increased 




1.3.2 Biosynthesis of NO 
 
NO is generated by enzyme-dependent and enzyme-independent pathways. A family 
of nitric oxide synthase (NOS) enzymes is responsible for catalyzing the conversion of 
cationic amino acid L-arginine to L-citrulline in the presence of O2 and NADPH (Figure 
1.1). NO synthesis is dependent on the redox status of the cell and critically influenced by 
various co-factors such as tetrahydrobiopterin (BH4), flavin mononucleotide (FMN) and 
flavin adenine dinucleotide (FAD), transition metals such as haem iron, the presence of 
reduced thiols  and , of course, substrate availability. Without an adequate delivery of 
substrate and co-factors, NOS no longer produces NO but instead transfers the free 
electrons to oxygen and thus produces oxygen-derived free radicals (superoxide anion 









NOS  isoforms in the heart 
 
To date, three mammalian NOS isoforms have been identified: neuronal (nNOS; 
encoded by the NOS1 gene), inducible (iNOS; encoded by the NOS2 gene) and 
endothelial (eNOS; encoded by the NOS3 gene) (Alderton et al., 2001). 
The genes for these isoforms are found on different chromosomes, the loci of which 
are shown the following Table 1.2 (Xu et al., 1994). 
 
Table 1.2. Gene loci of NOS isoforms 
 
Previous name Molecular Weight(kDa) Gene locus 
nNOS(NOS 1) 161 12q24.2-12q24.3 
iNOS(NOS 2) 131 17cen-q11.2 
eNOS(NOS 3) 133 7q35- 7q36 
Adapted from Ignarro, 2000. 
 
 
Each product of NOS genes share 50-60% amino acid homology (Figure 1.2). All 
three NOS isoforms, each of which is presumed to function as a homodimer during 
activation, share a carboxy-terminal reductase domain homologous to the cytochrome 
P450 reductases and an amino-terminal oxygenase domain containing a haem prosthetic 























Figure 1.2. The general structure of nitric oxide synthases and the variations among 
the isoforms. The enzyme has both oxidation and reductive functions and tends to 




Although originally classified as “constitutively expressed” and “Ca2+ sensitive”, the 
nNOS and eNOS are now known to be present in a number of cell types and to exhibit 
regulated expression under specific physiological conditions. Although constitutively 
expressed in many tissues, iNOS expression is generally considered to be present in 
pathological states. Its expression is readily increased in cardiomyocytes and 
inflammatory cells infiltrating the myocardium  in response to a number of chemical and 
mechanical stimuli and can be described as “ inducible” or “Ca2+  insensitive” (Ignarro, 
2000; Loscalzo et al., 2000). 
The three isoforms all produce NO, however, the differences in their structure allow 






eNOS which is originally characterized in large conduit vessel endothelium is now 
known to be expressed within the heart,  in the endothelium in both the endocardium and 
the coronary vasculature (including capillary and venular endothelium), in cardiac 
myocytes and in specialized cardiac conduction fiber, as well as in monocytes and 
platelets. eNOS is enriched in plasma membrane and T-tubular caveolae of cardiac 
myocytes, where it is associated with caveolin-3 (the myocyte-specific structural protein 
of caveolae).  Under resting conditions, NO synthesis by constitutively active eNOS 
mainly contributes to the regulation of vascular tone. It has been proposed to interact with 
β-adrenoceptors and L-type calcium channels, thereby attenuating calcium influx into the 
cardiomyocyte (Barouch et al., 2002).  
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The eNOS activity is increased by phosphorylation of its serine residue 1177 by 
activation of PI3-kinase and protein kinase B (Akt). In contrast, phosphorylation at the 
threonine residue 495 by AMP-activated kinase or protein kinase C can inactivate eNOS 






iNOS has been identified in cardiac myocytes, endothelium and inflammatory cells 
infiltrating the myocardium in response to stimulation with cytokines(e.g. TNF, IL-1β, 
IL-6) and/or lipopolysacharide (LPS). It was generally considered that iNOS is involved 
in early host defense against a primary infection, but studies have shown that iNOS –
induced inflammatory responses are not limited to the host defense against 
microorganisms. For example,  myocardium could produce large amounts of NO when 
stimulated with pro-inflammatory cytokines after acute myocardial infarction and MI/R 
(Haywood et al., 1996; Wildhirt et al., 1997; Wildhirt et al., 1999). On the other hand, 
excessive NO production is known to be involved in a wide range of inflammatory 
diseases (Ignarro, 2000).  The physiological roles of pathophysiological consequences 
following this high output of NO from iNOS in these cells are less clear. The 
physiological consequence of iNOS induction is not limited to a reversible decline in 
myocyte contractile function. NO also rapidly interacts with superoxide anions to 
produce the potent oxidant peroxynitrite (ONOO-). The formation of free oxygen radicals 
is increased during reperfusion, depending on duration and severity of the preceding 
ischemia. As such, with more severe and prolonged ischemia, free radical formation 
during the subsequent reperfusion is increased (Bolli et al., 1989), which will 
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subsequently increase the formation of peroxynitrite. High concentrations of peroxynitrite 
are thought to induce toxic cellular effects by oxidizing thiols or thioethers, protein 
nitration, initiation of lipid peroxidation, carbohydrates and DNA degradation. 
 The most convincing evidence for an important pathophysiological role for iNOS to 
date has come from clinical data. Patients with heart failure due to either ischemic heart 
disease or idiopathic dilated cardiomyopathy, are much more likely to have evidence of 
iNOS in endomyocardial biopsy and surgical specimens than control specimens, although 
these data do not provide evidence for the role of iNOS in postinfarction remodeling and 






The anatomic distribution and physiological role(s) of nNOS in the heart have been 
the least reported. In normal heart extracts, the nNOS is co-immunoprecipitated with the 
cardiac ryanodine receptor (RyR2), indirect evidence of its localization in the 
sarcoplasmic reticulum (SR), where it may respond to intracellular Ca2+ concentration 
and modulate SR Ca2+ ion active transport in the heart (Xu et al., 1999; Xu et al., 2003). 
It was also shown in nNOS knockout mice by demonstrating that nNOS activity mediates 
an inhibitory effect on cardiac sympathetic responsiveness in normal animals, as well as 
in animal models of cardiovascular diseases (Casadei, 2006). 
Notably, both nNOS and eNOS are constitutively expressed in cardiomyocytes,  but 
the distinct subcellular location dictates specific NO signaling from each isoform to 
respective, sometimes common, effectors in response to physical (e.g., stretch) or 
receptor-mediated stimuli (Barouch et al., 2002; Champion et al., 2001; Hare, 2004; Hare 
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et al., 1999). Genetic deletion or overexpression experiments are underway to help 
characterize each isoform’s respective role in the normal or diseased heart.  
 
1.3.3   Metabolism of NO in the mammalian circulation 
 
The charge neutrality of NO facilitates its free diffusion in aqueous solutions and 
across cell membranes as a second messenger. The biological effects of NO are 
dependent on its half-life, which are determined by the balance between the rate of NO 
formation and its metabolism. Various metabolic routes and reactions contribute to the 
breakdown and/or conversion of NO, e.g. heme proteins such as guanylyl cyclase, 
catalase, xanthine oxidase, superoxide dismutase (SOD) and hemoglobin, or high-energy 
free radicals such as the hydroxyl radical or carbon, oxygen- and nitrogen-centered 
radicals (Becker, 2004). The major immediate breakdown product of NO in plasma is 
nitrite (NO2-) (Kelm, 1999). Nitrite can be taken up by red blood cells, where it is 
oxidized in a hemoglobin-dependent manner to nitrate (NO3-), which can subsequently be 
redistributed into the plasma. 
 
1.3.4 NO and inflammation 
 
The production of NO in inflammation is generally considered a non-specific host 
defense mechanism of body against invading microorganisms and intracellular pathogens. 
Activated macrophages and neutrophils are able to kill a variety of microorganisms via 
NO-mediated response or NO-derived free radical. However, large amounts of locally 
produced NO are able to induce cytotoxic or cytostatic effects (such as the suppression of 
the mitochondrial respiratory chain, or induction of cell necrosis and apoptosis). 
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The most extensively studied inflammatory condition, with respect to the mechanism 
of iNOS expression, is systemic inflammation induced by LPS.  LPS is a potent 
stimulator of iNOS expression in many cells in vitro and species in vivo, which is 
mediated by NF-κB and interferon-regulatory factor-1(IRF-1) and also regulated by 
intracellular cyclic nucleotide level (Ignarro, 2000; Loscalzo et al., 2000; Morgan et al., 
2002; Murch et al., 2007). Many additional cytokines, microbial products, and lipid 
mediators were found to upregulate iNOS. And a diverse spectrum of immunoregulatory 
functions could be assigned to iNOS-derived NO.    
Although it is generally acknowledged that iNOS is the source of most NO produced 
in various forms of inflammation, it is also clear that sources other than iNOS can also 
contribute to the NO or reactive nitrogen intermediates under specialized conditions 
(Ignarro, 2000; Korhonen et al., 2005). 
However, it is found that NO exerts effects on anti-inflammation or in modulating 
inflammation and tissue injury in vitro and in vivo (DiMagno et al., 2004; Grisham et al., 
1999).  For example, exogenous NO could attenuate LPS-induced TF expression in 
monocytes by prior formation of peroxynitrite (Fiorucci et al., 2002c; Gerlach et al., 
1998).  
Besides exogenous NO donors which have been shown to attenuate leukocyte-
endothelial cell interactions in vitro, eNOS knock-out mice were employed to determine 
the role of NO in vivo by assessing the function of eNOS in modulating endothelial cell 
adhesion molecule expression, leukocyte adhesion, and extravasation. Significant 
increases in constitutive expression of adhesion molecules ICAM-1 and P-selectin were 
observed in the vasculature of tissues from eNOS knock-out mice compared to their wild-
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type controls (DiMagno et al., 2004). In addition, leukocyte rolling, adhesion, and 
extravasation were also increased in the eNOS knock-out mice. Finally, using a heart 
ischemia-reperfusion injury model, the eNOS knock-out mice showed increased 
neutrophil infiltration, ischemic zone, and infarct size. These data suggest that eNOS-
derived NO plays an important role in regulating endothelial cell adhesion molecule 
expression and leukocyte adhesion, as well as providing a protective effect in the 
postischemic heart (Grisham M et al., 2000; Jones et al., 1999; Jugdutt, 2002).  
 
1.4 NO Donor 
 
Dysfunction of the normal NO production and/or activity, especially eNOS, is found 
in several cardiovascular diseases, including coronary heart disease, hypertension, 
atherosclerosis and heart failure (Giraldez et al., 1997; Loscalzo et al., 2000). Indirect 
evidence demonstrated that the infusion of NO or administration of NO donor or its 
substrate (L-arginine), attenuated infarct size and neutrophil accumulation in in vivo 
models of regional myocardial ischemia-reperfusion (Smith et al., 1988; Tsao et al., 1990; 
Weyrich et al., 199; Vinten-Johansen et al., 1995; Jones et al., 2006). NO insufficiency 
may be due to an absolute deficit of NO synthesis, impaired availability of bioactive NO, 
or enhanced inhibition of NO endogenous production. Regardless of its pathological basis, 
NO insufficiency limits NO-mediated signal transduction of normal or protective 
physiological processes. There are several ways to increase the production and the effects 
of NO in the heart, e.g. by increasing NOS production and activity by gene-transfer or 
treatment with the available substrate for NOS, by administration of exogenous NO 
donor agents, or by increasing the bioavailability of NO after antioxidant treatment 
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(Champion et al., 2001). Of these methods, replacement or augmentation of endogenous 
NO by exogenously administered NO donors has been the simplest and most efficient 
solution for a broad field of pharmacotherapeutics in cardiovascular medicine (Ignarro et 
al., 2002). 
Organic nitrate and nitrite esters represent a class of NO-donating agents used in 
ischemic heart disease, heart failure, and hypertension since the 19th century. However, 
these clinically-administered nitrovasodilators (e.g. nitroglycerin and sodium 
nitroprusside) are limited by their short therapeutic half-life, systemic absorption with 
potentially adverse haemodynamic effects, and drug tolerance (Ignarro, 2000). The 
growth of interest in the study of NO since the mid 1980s has resulted in the birth of a 
variety of new NO donors that offer several advantages over conventional NO-donating 
agents.  
 
1.4.1   NO-Aspirin 
 
1.4.1.1 Overview of NO-Aspirin 
 
Recently, a new family of NO donor, called NO-NSAIDs (Nitric Oxide Non Steroidal 
Anti-Inflammatory Drugs) or CINODs (Cyclooxygenase-Inhibiting Nitric Oxide Donors) 
has emerged and extensively investigated (Keeble et al., 2002; Wallace et al., 1999). By 
linking an NO donating moiety to nonsteroidal anti-inflammatory drugs (NSAIDs), the 
NO donors were demonstrated the improved organ tolerability and new pharmacological 
profiles than their parent drugs due to NO itself and NO slow-releasing property (Keeble 
et al., 2002).  
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NO-Aspirin (2-acetoxybenzoate 2-(2-nitroxy-methyl)-phenyl ester, Figure 1.3), also 
called nitroaspirin or NCX-4016, is one of the leading compounds of NO-NSAIDs. 
 
                             
                         
                         Aspirin                                            NO-Aspirin 
 
Figure 1.3. Chemical structure of Aspirin (acetylsalicylic acid) and NO-Aspirin 
 
 
NO-Aspirin is a stable compound that requires enzymatic hydrolysis by esterases to 
liberate NO following metabolic digestion.  The release of NO from NO-Aspirin appears 
to be a slow and time-controlled kinetics (Gao et al., 2005; Minamiyama et al., 2007). In 
contrast to the NO generated by other NO-donors, the release of NO by NO-Aspirin 
within endothelial cells appears to take place in compartments near the plasma membrane, 
similar to the NO generated by endogenous eNOS (Fiorucci et al., 2002b). 
In rats, no NO-Aspirin was found in plasma at 0 to 24 h following oral administration 
of the drug, while salicylic acid, nitrites and nitrates (NOx) as well as S-nitrosothiols 
were detectable at 1 to 4 h after treatment (Carini et al., 2004a). After oral administration 
of NO-Aspirin to rats, increases in NOx were detectable in plasma for up to 10 h 
(Cuzzolin et al., 1996). After oral administration of NO-Aspirin to mice, once a day for 5 
days, plasma NOx levels were significantly increased with a peak at 3 h after the last 
treatment  (Momi et al., 2005). 
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After intraperitoneal administration of NO-Aspirin, high levels of the drug were 
found in the heart tissue where it released NO that was metabolized or stored in bioactive 
forms, such as S-nitrosothiols (Carini et al., 2004a). 
1.4.1.2 Effects of NO-Aspirin on inflammation 
 
The anti-inflammatory activity of NO-Aspirin has been extensively studied in vitro in 
cell cultures and in vivo in animal models of inflammation. The synthesis of thromboxane 
by activated human monocytes in vitro was inhibited by either aspirin or NO-Aspirin, but 
only NO-Aspirin reduced concentration-dependently the release of some cytokines (TNF-
α, IL-1β and IL-6) (Fiorucci et al., 1999; Minuz et al., 2001a; Minuz et al., 2001b). 
With oral administration to rats at 90 mg/kg daily for 5 days, NO-Aspirin prevented 
the expression of monocyte TF induced by the i.p. injection of lipopolysaccharide (LPS). 
This effect was accompanied by a reduction of plasma cytokine biosynthesis (TNF-α and 
IL-1β). In the same model, the NO-donor isosorbide mononitrate reproduced some of the 
effects of NO-Aspirin, while aspirin shared none of them. It has been suggested that the 
additive effects of NO release and COX inhibition may explain the improved anti-
inflammatory potency of NO-Aspirin (Fiorucci et al., 2002c). 
The biological activity of NO-Aspirin has been evaluated in a different experimental 
model to characterize its anti-inflammatory and antithrombotic effects. NO-Aspirin was 
more efficient than aspirin in inhibiting platelet activation (aggregation and adhesion) 
induced by thrombin, and it also inhibited the thrombin-induced aggregation of platelets 
pre-treated with acetylsalicylic acid in a dose-dependent manner (Lechi et al., 1996a; 
Lechi et al., 1996b). 
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1.4.1.3 Cardiovascular effect of NO-Aspirin  
 
NO-Aspirin protected the heart from ischemia-reperfusion (I/R) damage even by oral 
administration, a route of administration with which no unmodified NO-Aspirin has been 
found in the systemic circulation. It has been proposed that a NO-containing moiety can 
reach the heart where it can exert its NO-releasing activity (Carini et al., 2004a) 
The efficacy of NO-Aspirin was also tested in a model of coronary artery occlusion in 
rats with streptozotocin-induced diabetes. In non-diabetic animals, both aspirin and NO-
Aspirin reduced infarct size. In diabetic rats, however, infarct size was reduced by high 
doses of NO-Aspirin, but not aspirin (Burke et al., 2006) 
Myocardial protection of NO-Aspirin following myocardial ischemia-reperfusion 
(MI/R) has been assessed in several animal models. NO-Aspirin has been shown to 
improve postischemic ventricular dysfunction and to reduce overall mortality, myocardial 
dysfunction, myocardial infarct size and arrhythmias following ischemia and reperfusion 
in pigs (Wainwright et al., 2002), rabbits (Rossoni et al., 2004), as well as in rats 
(Rossoni et al., 2001). 
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1.4.2   NO-Paracetamol 
 
1.4.2.1 Overview of NO-Paracetamol 
 
Like NO-Aspirin, NO-Paracetamol(nitroacetaminophen or NCX-701: 4-
(nitroxy)butanoic acid 4-acetylaminophenyl ester) is the nitric oxide-releasing derivative 
of paracetamol which  is formed by linkage of a nitric oxide-releasing moiety to the 
parent compound (paracetamol) through an ester linkage. The chemical structures of NO-
Paracetamol and paracetamol are listed in Figure 1.4. 
 
                
 
                    
                       Paracetamol                                                        NO-Paracetamol 
 
 
Figure 1.4. Chemical structures of paracetamol NO-Paracetamol 
 
 
Compared with NO-Aspirin, fewer studies have focused on the catabolism of NO-
Paracetamol and the mechanism of NO release. Probably like other NO-NSAIDs, NO-
Paracetamol is broken down into NO and paracetamol by esterase hydrolysis in tissue or 
plasma. Moore et al. (Moore et al., 2003) demonstrated that NO-Paracetamol was 
chemically stable in aqueous buffer but NO (measurement of nitrate/nitrite or NOx) and 
free paracetamol in tissue homogenates in a time-dependent manner. Oral or 
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intraperitoneal administration of NO-Paracetamol leads to a time-dependent increase of 
both NOx and paracetamol in the plasma in the mouse (Fiorucci et al., 2002a) and rat 
(Moore et al., 2003). 
 
1.4.2.2 Effects of NO-Paracetamol on inflammation 
 
Based on available literature, paracetamol has little or no anti-inflammatory effect. 
With the addition of NO moiety, NO-Paracetamol exerts anti-inflammatory activity in 
different animal models of inflammation. For example, in a rat model of LPS-induced 
endotoxaemia, NO-Paracetamol prevented the increased plasma nitrate/nitrite and the 
expression of pro-inflammatory enzymes, such as COX-2 and iNOS, in lung, liver and 
kidney, whereas paracetamol exerted partial inhibition of COX-2 in lung alone (Marshall 
et al., 2006). Moreover, in the mouse model of the zymosan-induced pleural exudates, 
NO-Paracetamol produced dose-related inhibition of neutrophil migration into exudates 
(Moore et al., 2003). Furthermore, like NO-Aspirin which showed effects on 
carrageenan-induced hindpaw oedema formation, either i.p. or oral NO-Paracetamol 
administration in rats caused a dose- and time-related inhibition of hindpaw oedema 
formation. In marked contrast, paracetamol was completely devoid of anti-inflammatory 
activity in this model even at much higher doses (al-Swayeh et al., 2000). 
 
1.4.2.3 Cardiovascular effect of NO-Paracetamol  
 
With the same vasodilatory effect as other NO-NSAIDs, NO-Paracetamol relaxed the 
isolated blood vessel at high concentrations but had no significant effect on vascular 
function in vivo (Moore et al., 2003).  
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It was found in our laboratory that both paracetamol and NO-Paracetamol decreased 
the infarct size and increased the activities of catalase and SOD after acute MI when 
compared with the vehicle group via attenuating NOS and COX gene expression (Zhu et 
al., 2006). The exact mechanism of this cardioprotective effect is far from clear and 
worth further investigation.  
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1.5 Hydrogen Sulfide (H2S) 
 
1.5.1   A new member of gasotransmitter – H2S 
 
Soon after NO was discovered with the nature of endothelium-derived relaxing factor 
(EDRF), it became recognized as an important regulatory effector in almost all tissues. 
The discovery extended to the second inorganic gaseous molecule, carbon monoxide 
(CO), another toxic gas which is endogenously biosynthesized and is also an active 
gaseous mediator and neurotransmitter, although it is a much weaker signaling gas than 
NO. Recently, the studies on another toxic gas, hydrogen sulfide (H2S), have drawn the 
interests of scientists. These three gaseous molecules share many similarities as 
endogenous gaseous transmitters. Dr. Wang Rui recommended a new term, 
gasotransmittor, to define the three gaseous signaling transmitters criteria as below 
(Wang, 2002): 
 
• They are endogenously and enzymatically generated small molecules of gas 
• They are freely permeable to plasma membrane and their effects are member-
receptor independent 
• They have well-defined specific functions at physiological concentration 
• Their cellular effects not only are mediated by second messenger but work on 
specific cellular and/or molecular targets. 
 
To date, three gases have been identified as the gasotransmitters, namely NO, CO and 
the second interest of this thesis, H2S. 
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H2S is a colorless, water soluble gas with a strong characteritic smell of rotten eggs. It 
is naturally produced in the environment and from mammalian tissues. In aqueous 
solution and at pH 7.4, H2S dissociates into hydrogen ion H+ and hydrosulfide anion HS-, 
which subsequently may decompose to H+ and sulfide ion S2- at high pH. Of note, one 
third of H2S remains as undissociated form in an aqueous solution of pH 7.4 at room 
temperature (Wang, 2002). Sodium hydrosulfide (NaSH) is commonly applied as H2S 
donor since it dissociates to Na+ and HS-; HS- then binds H+ to form H2S. 
 
1.5.2   Biosynthesis of H2S 
 
H2S is produced endogenously in the most mammalian cell mainly by enzymatic 
catalyzing and less importantly by non-enzymatic (sulfur reduction) way.   
The only substrate for H2S enzymatic production is L-cysteine synthesized from L-
methionine. Two pyridoxal-5’-phosphate (PLP or vitamin B6)-dependent enzymes- 
cystathionine - β-synthase or CBS (EC 4.2.1.22) and cystathionine γ-lyase or CSE (EC 
4.4.1.1) - are responsible for H2S production. CBS and CSE have different expression 
levels in different tissues resulting in the different H2S concentrations for specific tissues 
or organs (Kamoun, 2004). The synthesis of H2S has been summarized in detail in these 
review papers (Lowicka et al., 2007; Szabo, 2007; Wang, 2002). 
CBS is detected mainly in the brain, liver and kidney. Using northern blot analysis, 
CBS was highly expressed in the rat hippocampus and cerebellum by brain homogenates 
in vitro (Abe et al., 1996), but CBS expression or activity was not detected in atrium and 
ventricular tissues of  humans (Chen et al., 1999) and rats (Kamoun, 2004). However, 
little or no CSE expression was found in the brain when applying CSE inhibitor in CBS-
deficient mice (Eto et al., 2002). CSE is found to be mainly expressed and responsible for 
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the production of H2S in the cardiovascular system. CSE mRNA has been detected in the 
pulmonary artery, tail artery, mesenteric artery, aorta, endothelium-free vascular smooth 
muscle, liver (Zhao et al., 2001), heart (Geng et al., 2004b) and kidney (Li et al., 2005). 
Incubating tissue with D, L-propargylglyicne (PAG), an irreversible inhibitor of CSE, 
significantly diminished H2S production in kidney (Li et al., 2005) and liver (Li et al., 
2005; Mok et al., 2004). Another CSE inhibitor, β-cyano-L-alanine (BCA), inhibits CSE 
in a competitive manner, but is less used than PAG.  
 
1.5.3   Metabolism of H2S  
 
Endogenous H2S is metabolized through three routes: 1) oxidation in mitochondria; 2) 
methylation in cytosol; 3) scavenged by methemoglobin or metallo- or disulfide-
containing molecules such as oxidized glutathione (Wang, 2002). H2S is readily oxidized 
in mitochondria to thiosulfate which is further converted to sulfite and sulfate. The sulfite 
is rapidly oxidized to sulfate by sulfite oxidase in mitochondria. Under physiological 
conditions, sulfate is a major end-product (like nitrate/nitrite for NO) of H2S metabolism 
which eventually is excreted by the kidney in either free or conjugated form (Lowicka et 
al., 2007). In the second route, H2S is also methylated in the cytosol by thiol S-
methyltransferase (TSMT) to methanethiol and dimethylsulfide. For the third route, H2S 
may bind to methemoglobin to form sulhemoglobin. As mentioned in the section of NO 
metabolism, hemoglobin becomes the common sink for H2S and NO. Considering the 
limited capacity of the hemoglobin sink, treatment with a new gasotransmitter could alter 
the availability and accumulated amount of a gas binding to hemoglobin (Lowicka et al., 
2007; Wang, 2002). 
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1.5.4    Physiological functions of H2S  
 
1.5.4.1 H2S and the cardiovascular system 
 
Effects on blood pressure and vascular tone 
 
H2S has been shown to play a role in the regulation of the vascular tone. Zhao et al. 
(Zhao et al., 2001) suggested that NaSH, a H2S donor, and H2S solution cause 
vasodilation on thoracic aorta concentration-dependently via activating KATP channel in 
vitro. Interestingly, immunohistochemical studies and RT-PCR revealed that CSE is 
expressed in vascular smooth muscle but not in endothelial cells. The vasodilatory effect 
also was observed in mesenteric arteries (Cheng et al., 2004) and portal vein (Hosoki et 
al., 1997). In vivo study demonstrated that the injection of exogenous H2S decreased 
blood pressure in anesthetized rats (Ali et al., 2006; Zhao et al., 2001). The available 
reports indicate that H2S relaxes blood vessels mostly by opening KATP channels in the 
vascular smooth muscle cells, but glibenclamide (a KATP channel antagonist) blocked the 
H2S-induced vessel relaxation. Moreover, CSE inhibitors reduced KATP channel current 
indicating the endogenous H2S continuously stimulated the channel under baseline 
conditions (Tang et al., 2005). 
 
Effect on the heart 
 
In the heart, administration of NaSH has a negative effect on myocardial contractility 
both in vitro and in vivo. This effect is attenuated, but not completely abolished by pre-
treatment with glibenclamide, suggesting only partial involvement of KATP channel (Geng 
et al., 2004b). Recent studies show that pre-treatment of H2S provided cardioprotective 
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effects in decreasing infarct size, the gold standard to assess cardiac injury in the animal 
model of permanent myocardial infarction (Zhu et al., 2007) and regional myocardial 
ischemia-reperfusion ex vivo (Johansen et al., 2006) and in vivo (Sivarajah et al., 2006). 
H2S was shown to produce cardiacprotective effects in preconditioning heart similar to 
that induced by ischemic preconditioning (Bian et al., 2006; Pan et al., 2006), while the 
exact mechanism of H2S-induced preconditioning needs to be further investigated. Elrod 
et al (Elrod et al., 2007) showed that H2S attenuated reperfusion injury in the mice by 
preservation of both mitochondrial structure and function. In addition, overproduction of 
H2S limited the extent of injury in CSE-overexpressed mice. 
 
1.5.4.2 H2S in inflammation 
 
Overproduction of NO by cytokine-induced iNOS contributes to vasodilation in 
septic shock. Like NO, H2S is also over produced in rats with experimental septic shock 
induced by coecal ligation and puncture, as well as in endotoxemic shock induced by 
lipopolysaccharide (LPS) administration (Hui et al., 2003). Scientists gradually found a 
surge of H2S formation in various inflammation models. Several studies demonstrated 
that plasma H2S concentration as well as CSE expression and activity in the liver and 
kidney are increased in LPS-treated mice (Li et al., 2005) and in cecal ligation and 
puncture mouse model of sepsis. Inhibition of H2S synthesis with PAG significantly 
decreased the inflammatory response as evidenced by different inflammatory indices 
such as lung and liver myeloperoxidase (MPO, a marker of neutrophil infiltration) 
activity, and plasma concentration of the cytokine tumor necrosis factor-α (TNF- α) 
(Zhang et al., 2007a). In contrast, administration of NaSH aggravated histological lesions 
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in the lung and liver as well as increased the tissue MPO activity and plasma TNF- α 
concentration. Similar effects of CSE inhibitor were also noted in the rat organ injury 
caused by endotoxemia (Collin et al., 2005) and LPS-treated mice (Li et al., 2005) as 
well as in the rat model of carrageenan-induced hid paw edema (Bhatia et al., 
2005a).Zhang ea al showed that H2S was an inflammatory mediator by upregulating the 
production of cytokines and chemokines via Nuclear Factor-κB(NF- κB) (Zhang et al., 
2007b). Thus, H2S not only contributes to hypotension but also augments the 
inflammatory response and organ damage associated with sepsis. 
Intriguingly, other studies in vitro suggested the anti-inflammatory potential of H2S. 
For example, in cultured RAW264.7 macrophages, H2S solution prepared by either 
bubbling pure H2S gas or NaSH was able to inhibit LPS-induced pro-inflammatory NO 
production by iNOS expression. Moreover, through the activation of the extracellular 
signal-regulated kinase (ERK), increased CO production and CO-mediated inhibition of 
NF- κB was noted (Oh et al., 2006). Moreover, in a rodent model of nonsteroidal anti-
inflammatory drug (NSAID) gastropathy, NaHS prevented the associated reduction of 
gastric mucosal blood flow (P < 0.05), reduced ASA-induced leukocyte adherence in 
mesenteric venules attenuated the gastric mucosal injury, and tumor necrosis factor 
(TNF)-alpha, intercellular adhesion molecule (ICAM)-1, and lymphocyte function-
associated antigen (LFA)-1 mRNA up-regulation induced by NSAIDs. However, 
Glibenclamide, a KATP channel inhibitor, and DL-propargylglycine(PAG), exacerbated  
gastric mucosal injury (Fiorucci et al., 2005). The similar results were observed in the 
carrageenan air pouch model in the rats.  H2S donors (NaHS and Na2S) inhibited aspirin-
induced leukocyte adhesion to the vascular endothelium, leukocyte infiltration, and 
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edema formation likely via activation of KATP channels. Again, the suppression of 
endogenous H2S synthesis through blockade of CSE, exacerbated the organ injury 
(Zanardo et al., 2006). In contrast with results (Bhatia et al., 2005a) applying PAG, an 
inhibitor of H2S synthesis, Zanardo et al. (2006) have observed that carrageenan-induced 
paw edema was suppressed by H2S donor via activation of KATP channels, and enhanced 
by another inhibitor of H2S synthesis, β-cyano-L-alanine (BCA). The discrepancies 
between these two studies deserve further investigation. 
Taken together, the data indicated that just like NO exerting multiple roles in 
inflammation, the functions of H2S in inflammation, either pro- or anti-inflammatory, are 
controversial. Whether neutrophil infiltration is involved in the effect of H2S in the 
inflammation process remains undefined. 
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1.5.5   H2S releasing NSAIDs 
 
Like NO-NSAIDs, H2S - releasing NSAIDs have been developed as a new class of 





Figure 1.5.   Chemical structure of S-diclofenac 
 
S-diclofenac (Figure 1.5), 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(3H-
1,2,dithiol-3-thione-5-yl)phenyl ester, has shown better anti-inflammatory activity  as 
evidenced by reduced lung and liver myeloperoxidase activity after lipopolysaccharideas 
injection and caused significantly less gastric toxicity than diclofenac (Li et al., 2007). 
 
















Table 1.3.  A summary of NO and H2S 
 
Aspect  Nitric oxide  Hydrogen sulphide  
Produced by 
mammalian cells?  
Yes, from L-arginine by NOS, 
as well as various  
non-enzymatic processes  
(for example, from nitrite 
under acidic conditions)  
Yes, from L-cysteine as a 
product of CBS and CSE, as 
well as a product of 
non-enzymatic processes in 
mammalian cells  
Diffusible, labile  
gas, rapidly eliminated 
by mammals?  
Yes,  
half-life of seconds and  
eliminated as nitrite and  
nitrate in urine  
Yes, short half-life and 
eliminated mainly as free and 
conjugated sulphate in the 
urine  
 
Bind to and reactions 
with hemoglobin?  
 
 
Yes, yield nitrosylhaemoglobin 
and methaemoglobin  
 
Yes, yield sulphaemoglobin 
Vascular effects?  
Yes, vasodilatation; mainly 
produced in endothelial cells 
under physiological conditions 
Yes, vasodilatation; only 
produced in smooth-muscle 
cells, not in endothelial cells  
Pro-inflammatory 
effects? 
Yes, higher concentrations can 
be toxic in its own right or via 
toxic metabolites mainly from 
iNOS 
Yes, at higher concentrations 




Yes, at low (physiological)  
concentrations;  
 





Yes, pre-treatment with NO 
donor 




Yes, increase derived from 
iNOS  unknown 
Gasotransmitter-
releasing derivatives of 
NSAIDs 
Yes, NO-NSAIDs,  
such as NO-Aspirin and NO-
Paracetamol.  
 
Yes, H2S- NSAIDs, 
e.g. S-diclofenac exerts  
 
Adapted from Nat Rev Drug Discov. 2007 Nov;6(11):917-35 (Szabo, 2007) 
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1.6 Research Interests and Objectives 
 
From the summary of NO and H2S in Table 1.3, we found that NO and H2S share 
numerous similarities - they are cell permeable labile gases, are synthesized in an 
extensive array of mammalian cell types from simple amino acids (arginine and cysteine), 
exert vasodilatory and cardioprotective effect, participate in inflammation (either pro- or 
anti-inflammatory), have their respective gasotransmitter-releasing derivatives of 
NSAIDs (e.g. NO-Aspirin and NO-Paracetamol),  pre-treatment with NO or H2S could 
provide cardioprotection.  
Aspirin (acetylsalicylic acid), the most widely prescribed drug in the world for the 
treatment of inflammatory conditions, inhibits COX in platelets, and therefore decreases 
thromboxane A2 and prostacyclin (PGI2) formation in infarcted heart. Although 
decreased thromboxane A2 synthesis is beneficial, a decline in PGI2 production is 
undesirable because PGI2  possesses cardioprotective action by inhibiting platelet 
aggregation (Yamamoto et al., 1999).  
NO-Aspirin, has been shown to be easily hydrolyzed by ubiquitous esterases in vivo 
into Aspirin and unchanged NO-donating moiety in the circulatory system (Carini et al., 
2004b), then NO release at a constant rate from NO-donating moiety in the same cell 
compartments as the endogenous NO derived from L-Arginine at the cellular level 
(Fiorucci et al., 2002b). NO can inhibit platelet aggregation (Radomski et al., 1990), thus 
counteracting the inhibition of PGI2 by the aspirin moiety. Moreover, anti-inflammation 
effects of NO-Aspirin have been studied in vitro and in animal models. It has been found 
to be involved in the inflammatory process of several cells (such as platelets, 
monocytes/macrophages, leukocytes, endothelial cells, smooth muscle cells) and interact 
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with different inflammatory targets (Bolla et al., 2006). Moreover, this compound exerts 
anti-arrhythmias and infarct-limiting activity through inhibition of neutrophil invasion 
and platelet aggregation in normal/diabetic rats and pigs following myocardial 
ischemia/reperfusion (MI/R) (Burke et al., 2006; Rossoni et al., 2001; Wainwright et al., 
2002). Thus, the first purpose of the thesis is to determine 
 
1. whether supplementation with NO to aspirin (by using NO-Aspirin) exerts 
better cardioprotective effects than aspirin does in MI/R?   
 
Another research interest is the role of H2S in the inflammation of myocardial 
ischemia-reperfusion. Reperfusion injury is characterized by a marked local and systemic 
inflammatory response that may exacerbate tissue injury and adversely affect left 
ventricular (LV)  function recovery (Frangogiannis et al., 2002; Maxwell et al., 1997). 
Disrupting inflammatory processes, such as recruitment of neutrophils, production of 
radical oxygen species, and activation of pro-inflammatory cytokines, have all modulated 
reperfusion injury (Frangogiannis et al., 2002).  
H2S exhibits pro-inflammatory activity in LPS-induced endotoxic shock (Collin et al., 
2005; Li et al., 2005) and in acute pancreatitis and associated lung injury (Bhatia et al., 
2005b). Severe acute pancreatitis was associated with lung injury characterized by 
neutrophil accumulation, which was attenuated by treatment with an irreversible inhibitor 
of H2S-synthesizing enzyme CSE, DL-propargylglycine (PAG) (Hosoki et al., 1997; 
Mok et al., 2004 ; Bhatia et al., 2005b). On the other hand, currently available studies 
support that H2S is beneficial for reperfusion injury in mice (Elrod et al., 2007)  and rats 
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(Johansen et al., 2006; Sivarajah et al., 2006). Hence, the second purpose of this thesis is 
to study 
 
2. the time course of H2S production during the MI/R. Is H2S a pro- or anti- 
inflammatory molecule in the inflammation induced by reperfusion? 
 
NO-Paracetamol (NOP) is a NO-releasing derivative of paracetamol (PARA) that 
confers an extra- or enhanced pharmacological profile compared with PARA by NO-
releasing moiety (Moore et al., 2003). Paracetamol, unlike Aspirin, is not found to be 
beneficial or harmful in the MI/R. Hence, we think that NO-Paracetamol is a better 
choice than NO-Aspirin as a NO-slow-releasing donor in the form of NO-NSAID to 
investigate the cardioprotection. L-arginine, the substrate for NOS, exerted different 
effects on post-ischemic myocardial injury when administered at different time points --- 
either at 10 min before reperfusion (early treatment) or 3 h after reperfusion (delayed 
treatment) (Liang et al., 2004). We are therefore also interested in the cardioprotective 
effects not only of pre-treatment, but also post-treatment with NO-Paracetamol in MI/R.  
 
Besides the numerous similarities between NO and H2S described in Table 1.3., the 
interaction of the two biological active gases is also investigated (Zhao et al., 2001; Ali et 
al., 2006).  For example, NO increased both H2S production and CSE expression in 
cultured smooth muscle cells (Zhao et al., 2001), and H2S interestingly augmented or 
inhibited the vasorelaxant effect of NO (Ali et al., 2006; Zhao et al., 2003a). So the third 
purpose of this thesis is to study 
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3. is to determine if NO-Paracetamol has cardioprotective effects as a NO-slow-
releasing donor. Is there any difference in the effects against the reperfusion 
injury between pre-treatment and post-treatment with NO donor? Could NO-
Paracetamol modulate H2S production in the reperfusion-induced 
inflammation? 
 
Aiming to answer the above questions, we established an in vivo experimental rat 
model of myocardial ischemia reperfusion and a validated method to measure left 
ventricular contractile function at first, and designed the thesis consisting of three 
experiments:   
 
Experiment 1: To evaluate the cardioprotective effect of NO-Aspirin in the rat model 
of MI/R and the possible mechanism(s) involved in the MI/R. 
 
Although NO-Aspirin were reported to have anti-arrhythmias and infarct-limiting 
activity through inhibition of neutrophil invasion and platelet aggregation in normal / 
diabetic rats and pigs following myocardial ischemia/reperfusion (MI/R) (Rossoni et al., 
2001; Wainwright et al., 2002; Burke et al., 2006), these effects against postischemic 
reperfusion injury are limited to 2-3 h and employing triphenyltetrazolium chloride (TTC) 
staining to assess infarcted myocardium. In the setting of brief ischemia followed by 
reperfusion, whether the reduction in 2,3,5-triphenyltetrazolium chloride (TTC) negative 
tissue observed in early reperfusion signifies genuine reduction of eventual infarct size 
following extended reperfusion is not clearly known. Because the stained myocardium 
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consists of a complex mixture of necrotic and surviving myocytes in the early reperfusion, 
at that time, the method of TTC staining has limitations in the accuracy with evaluation 
of cell necrosis (Miki et al., 1999). Furthermore, iNOS induced by pro-inflammatory 
cytokines could increase infarct size occurring in post-ischemia late phase ( up to 48 hour) 
reperfusion (Wang et al., 1999; Wildhirt et al., 1997; Wildhirt et al., 1999). 
Thus, in Experiment 1, NO-Aspirin was administered prior to the induction of MI/R 
(“pre-treatment”) and its cardioprotective effects were evaluated by infarct size and left 
ventricular function recovery at an extended reperfusion time point (48 h) compared with 
those in vehicle and aspirin groups against lethal reperfusion injury. We also investigated 
the effect of exogenous NO (NO-Aspirin) and NOS inhibitor on endogenous NOS 
expression and production to define NO role in ischemia-reperfused rats. 
 
Experiment 2:  To determine the time course of H2S production in the rat model of 
MI/R and investigate the role of H2S in the inflammation induced by MI/R 
 
Experiment 2 was designed to investigate the time course of endogenous H2S 
production during the reperfusion, and by administration of PAG (an inhibitor of H2S-
synthesizing enzyme CSE) and NaHS (a water-soluble H2S donor), the effects on the 
cardiac injury and LV function recovery and the role of H2S in the reperfusion-induced 
inflammation were also investigated. 
 
Experiment 3:  To investigate the cardioprotective effects of pre-treatment and 
post-treatment with NO-Paracetamol and the change of H2S production in the 
reperfusion-induced inflammation modulated by NO-Paracetamol in MI/R. 
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In this Experiment, not only was the cardioprotection of NO-Paracetamol compared 
to vehicle and paracetamol (its parent drug), it was also compared with the effects of the 
conventional NO donor, Sodium nitroprusside (SNP), which was applied as a positive 
control drug in this experiment. The possible infarct-limiting effects of post-treatment 
with NO-Paracetamol and SNP were also examined. Given the possible interaction 
between NO and H2S, we investigated the resulting change in H2S production by both 
















CHAPTER 2    MATERIALS AND METHODS 
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2.1    Animals  
 
Wistar rats (250-350g) were obtained from the Laboratory Animal Centre, National 
University of Singapore (NUS). Animals were housed under standard conditions and 
maintained in a diurnal 12 h light/dark cycle and fed standard rat chow and water ad 
libitum according to regulations of animal care by NUS and the project conforms to the 
‘Principles of laboratory animal care’ (NIH publication no. 85-23, revised 1985; 
http://grants1.nih.gov/grants/olaw/references/phspol.htm) which were approved by the 
animal ethics committee of NUS. 
 
2.2    Animal model of myocardial ischemia-reperfusion (MI/R) 
 
The procedure of animal heart exposure was introduced as described earlier (Ji et al., 
2003; Zhu et al., 2006; Zhu et al., 2000b). In brief, under anaesthesia, rats were intubated 
with a cannula which connected to a rodent ventilator, and artificially ventilated with 
room air. The rectal temperature was monitored and core temperature was maintained 
between 36.7°C and 37.3°C by placing on a controlled heating pad throughout the 
experiment. Left thoracotomy was performed at the third and fourth ribs, the ribs were 
gently spread using a small-sized retractor, and then the heart was exposed. For 
temporary occlusion of the left descending coronary artery (LCA), a 6/0 silk suture 
(Ethibond, Ethicon, Norderstedt, Germany) was placed around the artery 2-3 millimeters 
from the aortic root. The ends of the ligature were threaded through a polyethylene tube 
to produce a snare. After the completion of the surgical procedure, the heart was returned 
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to its normal position in the thorax. After 20 min of stabilization, regional ischemia was 
induced by tightening the snare against the ventricular wall and successful ischemia was 
verified by change in the color of the myocardium of left ventricle. After 25 min of 
ischemia, the snare was released and myocardial reperfusion was verified by change in 
the color of the ventricular myocardium. The thoracic cavity was then closed in layers by 
using 3/0 silk suture. Animals were sacrificed at different time points for biochemical and 
histological studies. Hearts were collected and immediately immersed in liquid nitrogen 




2.3    Experimental protocols 
All animals underwent an ischemia-reperfusion protocol of 25 min LCA occlusion 
followed by reperfusion time ranged from 1 to 72 hour and were randomly assigned to 
different treatment groups for the three independent experimental protocols. 
 
2.3.1   Experimental protocol 1 
 
Experimental protocol is illustrated in Figure 2.1.  The rats were randomly assigned to six 
different treatment groups, namely: group 1 (sham, n=14), sham-operated animals, 
thoracic open without left descending coronary artery (LCA) occlusion, daily treated with 
Tween 80 (vehicle); group 2 (vehicle +MI/R, n=23), vehicle-treated animals subjected to 
25 min of LCA occlusion followed by 48h of reperfusion; group 3 (ASA + MI/R, n=22), 
aspirin (30mg/kg/day)-treated animals and subjected to MI/R ; group 4 (NOA + MI/R, 
n=22), NO-Aspirin (NOA, 56mg/kg/day, NicOx Ltd , Sophia-Antipolis, France)-treated 
animals and subjected to MI/R, the dose of NOA was chosen to provide a dose equimolar  
with that of aspirin employed and based on reports showing cardioprotective effects at 
this dose (Rossoni et al., 2001; Wainwright et al., 2002); group 5 (L-NAME + MI/R, 
n=23), NG-nitro-L-arginine methyl ester (L-NAME, 20 mg/kg/day), a nonspecific 
inhibitor of endogenous NOS,-treated animals and subjected to MI/R and group 6 (NOA 
+ L-NAME + MI/R, n=20), NOA (56mg/kg/day)-treated animals followed 1h later by L-
NAME (20 mg/kg/day) and subjected to MI/R. All drugs dissolved in Tween 80, were 
administered orally (2 ml/kg) once a day for 7 consecutive days( from day 1 to day 7); on 
the 7th day (day 7), the last doses of drugs were administered 3 h before starting the 
 44
surgical operation. The tissue samples were collected 48 h after MI/R (day 9) for 







Figure 2.1. Summary of experimental protocol 1.  
 
After instrumentation and stabilization, all rats were subjected to 25 min regional 
ischemia and 48 hour reperfusion. For details of treatment see text. IS, ischemia by 
coronary artery occlusion; ASA, aspirin; NOA, NO-Aspirin; BP, blood pressure; HR, 
heart rate.  
 




7 days  Reperfusion for 48h 
IS 
Pre-surgical treatment with Vehicle or 








 (BP and HR)  




(BP and HR) 
Plasma NOx  
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2.3.2   Experimental protocol 2 
 
The CSE mRNA and activity were determined at the end of ischemia and 1, 4, 24, 48, 
72 hour after initiation of MI/R in the rats ( Figure 2.2). Then the role of MI/R-induced 
H2S was further investigated by administration of PAG and NaHS (Figure 2.3). Rats were 
randomly assigned to one of the six groups: group 1, sham-operated animals, thoracic 
open without left descending coronary artery (LCA) occlusion, treated with 1 × PBS 
(vehicle) at the 25 min of ischemia; group 2, MI/R  and treatment with 1 × PBS (vehicle) 
at the 25 min of ischemia; group 3,  MI/R  and post-treatment with PAG (7.5 mg/kg/day, 
i.p.) at the 25 min of ischemia; group 4,  MI/R  and post-treatment with PAG (20 
mg/kg/day, i.p.) at the 25 min of ischemia; group 5 MI/R  and post-treatment with PAG 
(40 mg/kg/day, i.p.) at the 25 min of ischemia; group 6, MI/R  and NaHS (300 µg/kg/day, 
pump implantation at the end of 25 min ischemia). The method of pump implantation is 
described in this chapter. Rats were sacrificed at 4, 24 and 48 hours after myocardial 









Figure 2.2. Experimental protocol 2: the time course of H2S production in the rat 
model of MIR.  
 
After instrumentation and stabilization, rats were subjected to 25 min regional ischemia 
and reperfusion time ranging from 1 hour to 72 hours. IS, ischemia by coronary artery 
occlusion; MI/R, myocardial ischemia-reperfusion. 
 
 
  Reperfusion  
IS 
CSE mRNA and activity at the end of ischemia and 1, 4, 











Figure 2.3. Summary of experimental protocol 2: rats were treated with vehicle, 
PAG and NaHS.  
 
After instrumentation and stabilization, rats were subjected to 25 min regional ischemia 
and 4, 24 and 48 hour reperfusion. For details of treatment see text. IS, ischemia by 
coronary artery occlusion; LV function, left ventricular function.  
 





  Reperfusion for 48h  
IS 
48h 
Infarct size  
LV function 
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Post-surgical treatment with vehicle, PAG and NaHS 
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2.3.3   Experimental protocol 3  
 
Experimental protocol is illustrated in Figure 2.4. Rats were randomly assigned to one 
of the eight  treatment groups, namely: group 1, sham-operated animals; group 2 vehicle 
(10% Tween 20 dissolved in 0.9% sodium chloride, i.p.) -pre-treated animals subjected to 
25 min of LCA occlusion followed by 24h of reperfusion; group 3 paracetamol 
(16mg/kg/day i.p.) pre-treated animals and subjected to MI/R ; group 4, NO-Paracetamol 
(10 or 30mg/kg/day, NicOx Ltd , Sophia-Antipolis, France) pre-treated animals and 
subjected to MI/R, the dose of 30 mg/kg NO-Paracetamol was chosen to provide a dose 
equimolar  with that of 16mg/kg paracetamol; group 5, SNP (31.7 mg/kg/day via  pump 
implantation, the mol for mol of  the  30mg/kg/day NO-Paracetamol) pre-treated animals 
and subjected to MI/R; group 6, MI/R  and 3 hours later, i.p. post-treatmented with 
vehicle solution; group 7, MI/R  and 3 hours later, post-treatment with NO-Paracetamol 
(30mg/kg/day i.p.); group 8, MI/R  and 3 hours later, post-treatment with SNP (31.7 
mg/kg/day via  pump implantation). For groups 3 and 4, drugs were pre-treated once a 
day for 3 consecutive days (from day 1 to day 3), on the day 3, the last doses of drugs 
were administered 3 h before the surgical operation. For group 5 and 8, SNP was 
dissolved in the vehicle solution and filled into the pump as described in this chapter. 
Rats were sacrificed at 4 and 24 hours after myocardial ischemia for left ventricular 



















Figure 2.4. Summary of experimental protocol 3.  
 
After instrumentation and stabilization, all rats were subjected to 25 min regional 
ischemia and 48 hour reperfusion. For details of treatment see text. IS, ischemia by 
coronary artery occlusion; Para, paracetamol; NOP, NO-Paracetamol; BP, blood 
pressure; HR, heart rate; LV function, left ventricular function.  
 
Note: Pre- or post-surgical treatment is also written as “pre- or post-treatment” in the text. 
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2.4    Experimental methods 
2.4.1   Systemic blood pressure (BP) and heart rate (HR) measurement 
 
BP and HR measurements were done, using the NIBP (Non-invasive Blood Pressure) 
System (ML125/R, ADInstruments Powerlab System, USA) and electrocardiogram (ECG) 
monitor (ML 136, ADInstruments Powerlab System, USA) as previously (Zhu et al., 
2006). 
 
2.4.2   Measurement of LV haemodynamic parameters 
 
Animals were anaesthetized i.p. with a combination of ketamine (87 mg/kg) and 
xylazine (13 mg/kg), supplied by Animal Holding Unit of the National University of 
Singapore). The LV was then cannulated using a polyethylene tube (PE 50; Becton-
Dickinson) into the right carotid artery and advanced into the LV via the ascending aorta. 
During cannulation, the catheter was connected to a transducer and blood pressure 
monitor to verify the position of the tip of the catheter. The LV was considered to be 
reached when the pulse pressure had a typical LV-configuration. The left ventricular 
developed pressure (LVDevP), expressed as the difference between systolic and diastolic 
pressures were measured and the maximal slopes of systolic pressure increment (LV + 
dP/dt max) and diastolic pressure decrement (LV - dP/dt max), indexes of contractility 
and relaxation , were measured by a pressure transducer (MLT 844 high precision BP 
transducer, AD Instruments, California) and recorded using a MacLab A/D converter 
(AD Instruments, Mountain View, California). 
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2.4.3   Determination of infarct size 
 
The area at risk and infarct size were evaluated with 2,3,5-triphenyltetrazolium 
chloride (TTC) and Evans Blue dye, as previously reported (Ji et al., 2003) and (Clark et 
al., 1980) respectively. In brief, at the end of the 2-h reperfusion period, the ligature 
around the LCA was retightened and 1 ml of Evans blue dye (2% w/v) was injected 
intravenously into the jugular vein to delineate ischemic (area at risk) and nonischemic 
myocardium (area not at risk). The Evans blue solution stains the perfused myocardium, 
while the nonperfused myocardium remains uncolored. The rat was euthanized with a 
15% KCl solution and the heart was rapidly excised, rinsed, and blotted dry. After 
removing the atria, right ventricle wall, and the major blood vessels, the left ventricle was 
sliced parallel to the atrioventricular groove in 3-mm-thick sections. The area at risk of 
the left ventricle (unstained portion) was separated from the area not at risk of the left 
ventricle (stained portion). The area at risk was again sectioned into 1-mm-thick slices 
and incubated in a 1% (w/v) solution of the triphenyltetrazolium chloride stain in 20mM 
phosphate buffer (pH 7.4) at 37°C for 20 min. The tetrazolium dye forms a blue formazan 
complex in the presence of coenzymes and  dehydrogenases. The irreversibly injured 
necrotic portion of the myocardium, which did not stain, was separated from the stained 
portion (i.e., ischemic but non-necrotic area at risk). All portions of the left ventricular 
myocardium were weighed and stored at - 80°C for subsequent assay of myeloperoxidase 




 2.4.4   Measurement of plasma nitrate/nitrite 
 
Nitrate/nitrite (NOx) was determined in plasma collected immediately at the end of 
48 h after surgery. Briefly, intracardiac blood samples (0.5 ml) were collected. The blood 
was centrifuged for 15 min at 2,400g at 4°C and the plasma supernatant was removed and 
stored frozen at -80°C until assayed. NOx was determined spectrophotometrically in 
aliquots (80 µl) of plasma using the Greiss reagent as described (Zhu et al., 2006). In 
brief, aliquots of plasma were incubated (37°C, 30 min) with nitrate reductase (10 mU) in 
the presence of NADPH (100 µM) to reduce nitrate to nitrite and then centrifuged 
(14,000 g, 25 min, 4°C). The resulting supernatant and sodium nitrite standard (100 µl; 
0.125−75 µM) were added in duplicate to 96-well microtiter plates. Thereafter, Greiss 
reagent (containing 0.2% N-1-naphtyl ethylenediamine dihydrochloride and 2% w/v 
sulfanilamide in 5% v/v H3PO4) was added to the above mixture in a ratio of 1:1 (v/v) 
and incubated for 10 min at room temperature after which absorbance was determined at 
550 nm in a 96-well microplate reader (Tecan Systems Inc.). The concentration of nitrite 
(indicative of NOx in the original samples) was calculated from a standard curve of 




2.4.5   RNA extraction and reverse transcriptase – polymerase chain reaction (RT-
PCR) amplification 
 
Total RNA was extracted according to standard protocol (Zhu et al., 2000a). Briefly, 
1μg total RNA of each sample was reverse-transcribed into first-strand complementary 
DNA (cDNA) and amplified using one step reverse transcriptase polymerase chain 
reaction (RT-PCR) kit (Qiagen, Germany). Briefly, 1μg of RNA from each pooled 
sample was used in RT-PCR. The RT-PCR was carried out in a total volume of 20μl, 
containing 4μl of Qiagen OneStep RT-PCR buffer, 0.8μl dNTP, 1.2μl of sense primer, 
1.2μl of anti-sense primer, 0.8μl Qiagen OneStep RT-PCR Enzyme Mix. RT-PCR was 
carried out in a thermocycler (GeneAmp PCR System 2700). Firstly, the samples were 
incubated at 50°C for 30 minutes to allow reverse transcription for the synthesis of cDNA. 
Following thus, the samples were subjected to PCR amplification using primers specific 
for COX-1, COX-2, eNOS, nNOS, iNOS, CSE and GAPDH. Three-step PCR of 
denaturing and extension were carried out at 94°C for 30 seconds, 55°C for 45 seconds, 
72°C for 30 seconds respectively. The PCR products were in linear and did not yet reach 
plateau. The annealing temperature and PCR cycle for different genes were set as follows: 
GAPDH (55°C for 30 seconds, 25 cycles), CSE (58.5°C for 30 seconds, 36 cycles) and 
COX-1, COX-2, eNOS, nNOS, iNOS (55°C for 30 seconds, 35 cycles). The reaction 
without RNA template (none template control) was also performed as a negative control. 
PCR products were analysed by 1.5% wv-1 agarose ethidium bromide gel electrophoresis 
and imaged under ultraviolet light by the MultiGenius Bioimaging system (Syngene, 
Cambridge, U.K.). The band intensity was semiquantified by densitometry using Gel 
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analysis software (Syngene, Cambridge, U.K.).The primer sequences and their product 




Table 2.1. Gene sequences and corresponding product sizes of GADPH, COX-1, 










sense 5’-CGAGGATGTCATCAAGGAG-3’  
antisense 5’-TCAGTGAGGCTGTGTTAACG-3’ 


















sense 5’-CATGGATGAAGTGTATGG AGGC-3’  







COX, cyclooxygenase; NOS, nitric oxide synthase; eNOS, endothelial NOS;  





2.4.6   Implantation of osmotic pumps 
 
ALZET® Osmotic Pumps are miniature, infusion pumps for the continuous dosing of 
laboratory animals as small as mice and young rats. In our study, the implantable osmotic 
pump (Alzet® 2ml Model) was employed for the NaHS and SNP administration in 
experimental rats with MI/R.  This pump delivered drug continuously for 7 days and 
released drug constantly at 10±1.5µl/h.  The filling and handling of the pumps as well as 
the surgical implantation procedures were all performed under sterile conditions.  Before 
implantation, the pump body was filled up with drug using a 3 ml syringe and the blunt-
tipped, 25 gauge filling tube provided by the supplier.  The syringe and the attached tube 
were carefully kept free of air bubbles, followed by flow moderator fully inserted into the 
body of pump.  The filled pump was then incubated in sterile saline at 37ºC overnight.  
The osmotic pump was implanted subcutaneously at the nape of each rat under 
anesthesia.  For subcutaneous implantation, a small incision was cut in the skin using 
scapulae.  A small pocket was then made by spreading the subcutaneous connective 
tissue apart with a hemostat.  The pump pre-filled with drug was inserted into the pocket 
with the flow moderator pointing away from the incision.  The implantation was 
completed by closing the skin incision with 4-0 silk suture (Ethicon, Germany).  
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2.4.7   Assay of tissue H2S  
 
Ischemic heart tissues from animals treated as above were thawed and homogenized 
in 100mM ice-cold potassium phosphate buffer (pH 7.4). Optimal w/v ratios of 1:20 w/v 
were determined from preliminary experiments. The reaction mixture (total volume, 500 
µl) contained L-cysteine (10mM, 20 ml), pyridoxal 50-phosphate (2mM, 20µl), saline 
(30 µl) and tissue homogenate (430 µl). The reaction was performed in parafilmed 
eppendorf tubes and initiated by transferring the tubes from ice to a water bath at 37°C. 
In some experiments, the enzymatic reactions were stopped immediately by addition of 
trichloroacetic acid (10% wv-1, 250 µl) to denature protein prior to addition of cysteine. 
After incubation for 30 min, zinc acetate (1% wv-1, 250 µl) was added to trap evolved 
H2S, followed by tricholoroacetic acid. Subsequently, N,N-dimethyl- phenylenediamine 
sulphate (20 µM, 133 ml) in 7.2M HCl and FeCl3 (30 mM, 133 µl) in 1.2M HCl were 
added and the absorbance of the resulting solution (670 nm) measured 15 min thereafter, 
using a 96-well microplate reader (Tecan Systems Inc., San Jose, CA, U.S.A.). The basal 
concentration of H2S was determined in incubates in which trichloroacetic acid was 
added at zero time (T=0) prior to addition of cysteine and incubation (37°C, 30 min). At 
the end of this period, trichloroacetic acid was added and H2S generated assayed 
spectrophotometrically as described above. All samples were assayed in duplicate. The 
H2S concentration of each sample was calculated against a calibration curve of sodium 
hydrosulphide (NaHS; 3.12–250 mM) and results are expressed as nmol H2S formed mg-1 
soluble protein (determined using the Bradford assay, Bio-Rad Ltd, Hercules, CA, 
U.S.A.). 
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2.4.8   Myocardial myeloperoxidase activity (MPO) 
 
After determining infarct size, tissue samples from the ischemic zones( at risk) were 
frozen in liquid nitrogen and immediately stored in -80 freezer for analysis of MPO 
activity. 
Neutrophil sequestration in area at risk was quantified by measuring tissue 
myeloperoxidase (MPO) activity. Tissue samples were thawed, homogenized in 20 mM 
phosphate buffer (pH 7.4), centrifuged (10,000 × g, 10 min, 4°C) and the resulting pellet 
resuspended in 50 mM phosphate buffer (pH 6.0) containing 0.5% w/v hexadecyl 
trimethylammonium bromide (Sigma). The suspension was subjected to four cycles of 
freezing and thawing and further disrupted by sonication (40 seconds). The sample was 
then centrifuged (10,000 × g, 5 min, 4°C) and the supernatant used for the MPO assay. 
The reaction mixture consisted of the supernatant (50 μl), 1.6 mM tetramethylbenzidine 
(Sigma), 80 mM sodium phosphate buffer (pH 5.4), and 0.3 mM hydrogen peroxide 
(reagent volume: 50 μl). This mixture was incubated at 37°C for 110 sec, the reaction 
terminated with 50 μl of 0.18 M H2SO4 and the absorbance measured at 450 nm. This 
absorbance was then corrected for the wet weight of the tissue sample and results are 




2.4.9   Myocardial cytokine assay 
 
For the measurement of cytokines (IL-1beta, IL-6, TNF-alpha) in 
homogenized ischemic heart zone (50mg heart tissue homogenized in 100 mM ice-cold 
potassium phosphate buffer pH 7.4), ELISA kits  (R&D Systems) were used according to 
the manufacturer’s instructions. The catalogue numbers for IL-1beta, IL-6, TNF-alpha 
are Cat # DY501, Cat # DY506 and Cat # DY510 respectively. The ELISA assay for the 
three cytokines gave reproducible results with interassay variability of less than 9.5% and 
intra-assay variability of less than 6.5%. Results were then corrected for the soluble 
protein content of the tissue samples and were expressed as pg/mg soluble protein. 
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2.5    Statistical analysis 
 
Results indicate mean ± S.E., with the number of observations shown in parenthesis. 
Statistical significance of differences between groups of data was determined by one-way 
analysis of variance (ANOVA) with post-hoc Tukey’s test. A probability (P) value of less 








































3.1    Results of Experiment 1: Cardioprotective Effects of Nitric Oxide-
Aspirin in Myocardial Ischemia-reperfused Rats 
 
3.1.1   Mortality and infarct size 
 
The results of the infarct size and mortality in MI/R rats are reported in Table 3.1. 
Mortality rate for vehicle- (n=23), aspirin- (n=22) and NOA (n=22)-treated groups were 
34.8%, 27.3% and 18.2% respectively. Although there was no significant difference 
when comparing any two groups, NOA and aspirin tended to reduce the mortality rate 
and more rats in the NOA-treated group survived than those in the aspirin-treated group. 
In contrast, L-NAME had a higher mortality rate (45.0%) than the vehicle -treated group 
(34.8%); however, with co-administration of NOA with L-NAME, the higher mortality of 
L-NAME was abrogated (34.8%). 
There were no significant differences in body weight (BW), heart weight (HW) and 
left ventricle weight (LVW) among all groups. A corresponding reduction in infarction 
size in the groups with better survival rate was noted. Thus, infarction size (n=5) for the 
vehicle group was 44.5%± 2.7% of the left ventricle (LV) while the infarction size for 
aspirin and NOA groups was reduced to 36.7%± 1.8% and 22.9%± 4.3% of the LV 
respectively. Infarct sizes were significantly decreased in both aspirin- and NOA- treated 
groups as compared to the vehicle group (P < 0.05). There was also a significant 
difference observed between aspirin- and NOA-treated groups (P<0.05). Compared to 
vehicle group, treatment with L-NAME increased infarct size (P <0.05) and completely 













 BW HW LVW infarct size Mortality(n) 
 g g g   
Sham 259.5±4.3 0.782±0.018 0.490±0.022 0 0(14) 
Vehicle 255.0±7.5 0.866±0.037 0.530±0.035 44.5±2.7 34.8(23 ) 
Aspirin 255.4±4.4 0.804±0.026 0.504±0.020 36.7±1.8a 27.3(22 ) 
NO-Aspirin 
(NOA) 244.5±4.3 0.808±0.040 0.514±0.035 22.9±4.3
a, b 18.2(22 ) 
NOA+ 
L-NAME 248.0±10.3 0.838±0.031 0.532±0.020 42.0±4.2 34.8(23 ) 
L-NAME 257.9±7.5 0.796±0.030 0.464±0.030 55.0±2.6a 45.0(20 ) 
Table 3.1. BW, HW, LVW, Infarct size and Mortality in rats treated with vehicle, 
aspirin, NOA, NOA+L-NAME and L-NAME.  
Rats were subjected 25 min of coronary artery occlusion followed by 48 h of reperfusion. 
BW, body weight; HW, heart weight; LVW, left ventricle weight.  
Values are means ± S.E.  





3.1.2   Systemic BP and HR 
 
6-8 rats from each treatment group were randomly selected for the measurement of 
systemic BP and HR. Systemic BP and HR were measured (Table 3.2) at 3 time points: 
just prior to starting drug treatment (baseline), at 1 h after last drug treatment on day 7, 
and at 48 h after the onset of reperfusion (end of reperfusion). Baseline BP values were in 
the same range in all treatment groups. After 7-day treatment, BP in NOA-treated group 
showed a slight but not significant decrease compared to that in vehicle group. 
In L-NAME-treated group, systemic BP significantly increased after 7-day treatment 
but markedly decreased at the end of 48 h reperfusion compared with vehicle group ( p < 
0.01). In L-NAME co-administered with NOA, NOA abolished L-NAME-induced 
systemic BP increase (P > 0.05) and attenuated L-NAME-induced BP decrease at 48 h 
reperfusion (P < 0.05 in NOA-treated group vs.  P < 0.01 in L-NAME-treated group). 
Baseline HRs were in the same range and remained unchanged after treatment and at 
48 h reperfusion in rats treated with vehicle, aspirin and NOA. L-NAME had no effect on 







 Day 1 (Baseline) Day 7 Day 9 
Systemic BP (mmHg)    
Vehicle 119.0±3.9 123.7±3.4 116.6±3.4 
Aspirin 123.9±3.6 119.0±3.8 106.8±4.9 
NO-Aspirin (NOA) 122.4±4.9 113.7±3.2 111.8±4.6 
NOA+ L-NAME 124.5±4.4 128.7±4.1 104.2±1.7a 
L-NAME 124.2±5.1 138.4±1.0a 97.5±3.5b 
HR (Beat/min)    
Vehicle 425±13 434±15 431±13 
Aspirin 451±14 426±19 445±7 
NO-Aspirin (NOA) 447±11 445±10 432±10 
NOA+ L-NAME 429±17 437±13 461±13 
L-NAME 429±22 441±10 423±11 
Table 3.2. Systemic BP and HR on day 1, day 7 and day 9 in rats treated with 
vehicle, aspirin, NOA, NOA+L-NAME and L-NAME.  
Day 1, baseline levels before drug administrations; Day 7, after 7 consecutive days of  
drug administrations; Day 9, 48 h after the surgical procedure. BP, systemic blood 
pressure; HR, heart rate.  
Values are means ± S.E.(n=6-8).  





















3.1.3   Parameters of left ventricular function  
 
Figure 3.1. and Table 3.3 depict the left ventricular mechanical function parameters at 
48 h reperfusion including LVDevP, LVSP, LV + dP/dt max and LV - dP/dt max. 
Compared with sham group, significant decreases in LVDevP, LV + dP/dt max, LV - 
dP/dt max were noted in rats subjected to MI/R. Figure 2.1 depicts that NOA improved 
significantly LVDevP from reperfusion injury compared to sham group (N.S.) while 
other treatment had no such influence (P <0.05 vs. sham group). NOA and aspirin 
appeared to increase, although not significantly, LVSP, LV + dP/dt max and LV - dP/dt 
max (N.S.) compared with vehicle group, which demonstrates that the left ventricular 
mechanical function recovered partly from reperfusion injury (Table 3.3). However, L- 
NAME tended to decrease LVSP, LV + dP/dt max and LV - dP/dt max as compared to 







































Figure 3.1. LVDevP (mmHg) at 48 h reperfusion in rats treated with vehicle, aspirin, 
NOA, NOA+L-NAME and L-NAME.  
Rats were subjected to 25min of coronary artery occlusion followed by 48 h of 
reperfusion.  
Values are means ± S.E.(n= 5-7).   









 LVSP LV +  dP/dt max LV - dP/dt max 
 mmHg ×1000 mmHg/s ×1000 mmHg/s 
Sham 103.5±4.9 4.7±0.4 3.0±0.2 
Vehicle 92.3±3.6 3.1±0.3a 2.1±0.3a 
Aspirin 89.1±5.4 3.5±0.3a 2.3±0.3 
NO-Aspirin (NOA) 96.4± 1.5 3.3±0.2a 2.3±0.2 
NOA + L-NAME 87.2±2.5a 3.0±0.2a 1.7±0.2b 
L-NAME 85.0±4.2a 2.7±0.3a 2.1±0.3a 
Table 3.3 LVSP, LV + dP/dt max, LV - dP/dt max in rats treated with vehicle, 
aspirin, NOA, NOA+L-NAME and L-NAME.  
Rats were subjected to 25min of coronary artery occlusion followed by 48 h of 
reperfusion.   
Values are means ± S.E.(n= 5-7).   




3.1.4   Plasma nitrite/nitrate (NOx) concentrations  
 
NOx concentrations in plasma were shown in Figure 3.2. Treatment with NOA for 7 
consecutive days caused a marked increase of plasma NOx (P < 0.05 vs. sham and 
vehicle group). Rats subjected to MI/R (vehicle group, 33.3±1.5 μM) showed a higher 
NOx level compared to sham group (17.6±2.4 μM, P <0.05). Aspirin (25.6±2.1 μM) and 
NOA (17.3±1.6 μM) showed attenuation of NOx level compared to vehicle group, but 






































Figure 3.2. Plasma NOx concentration (μM) in rats treated with vehicle, aspirin, 
NOA, NOA+L-NAME and L-NAME. 
Rats were subjected to 25min of coronary artery occlusion followed by 48 h of 
reperfusion. Open bars represent NOx value of rat sacrificed just before MI/R. Close bars 
represent NOx value of rat sacrificed 48 hour after MI/R.  
Values are means ± S.E.(n=4-6).  




3.1.5   Gene expression of NOS and COX  
 
The gene expressions for NOS and COX are shown in Figure 3.3 (A-E). All treatment 
groups had no significant influence on COX-1, eNOS and nNOS mRNA expressions 
compared to those in vehicle-treated animals after 48 h reperfusion. The level of iNOS 
mRNA expression increased significantly in vehicle group compared to that in the sham 
group (2.6-fold), but compared with that in the vehicle group, it decreased in Aspirin 
(0.64-fold, P <0.05) and NOA (0.37-fold, P <0.01) groups. The COX-2 mRNA level 
increased significantly too in vehicle group compared to sham group (2.5-fold). There 
were significantly lower levels of COX-2 production in aspirin-, NOA-treated groups (P 
< 0.01) compared to the vehicle group. L-NAME administration did not alter the increase 
in iNOS and COX-2 expression but did reverse the NOA-induced inhibition of 
expression of these genes. 
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Figure 3.3. Gene expressions of NOS and COX in rats treated with vehicle, aspirin, 
NOA, NOA+L-NAME and L-NAME.  
 
(A), inducible (iNOS); (B) neuronal (nNOS), (C) endothelial  nitric oxide 
synthase(eNOS), (D) cyclooxygenase-1 (COX-1) and (E) COX-2 in sham, vehicle, 
aspirin, NOA, NOA + L-NAME and L-NAME pre-treated rats  subjected to 25min of 
coronary artery occlusion followed by 48 h of reperfusion.  
Values are means ± S.E. (n=3) 
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C)
Lane 1 = sham;  
Lane 2 = vehicle;  
Lane 3 = Aspirin; 
Lane 4 = NO-Aspirin (NOA);  
Lane 5 =NOA + L-NAME; 





































                         
 
 
Figure 3.3. Gene expressions of NOS and COX in rats treated with vehicle, aspirin, 
NOA, NOA+L-NAME and L-NAME.  
(A), inducible (iNOS); (B) neuronal (nNOS), (C) endothelial  nitric oxide 
synthase(eNOS), (D) cyclooxygenase-1 (COX-1) and (E) COX-2 in sham, vehicle, 
aspirin, NOA, NOA + L-NAME and L-NAME pre-treated rats  subjected to 25min of 
coronary artery occlusion followed by 48 h of reperfusion.  
Values are means ± S.E. (n=3) 
































3.2    Results of Experiment 2: Role of Hydrogen Sulfide in the Rat 
Model of MI/R 
 
3.2.1   CSE mRNA expression in the ischemia left ventricle 
 
The abundance of the mRNAs for CSE and GAPDH in the ischemic left ventricle 
from the rats subjected to ischemia-reperfusion and the sham-operated control rats was 
determined by RT-PCR. The level of each CSE mRNA was normalized to that of 
GAPDH.  
Figure 3.4 displays the CSE mRNA results of sham control and MI/R groups at 
different reperfusion times in the ischemic left ventricle (each point represents 4-6 
independent experiments). The level of CSE/GADPH ratio significantly decreased at 
30min after initiation of ischemia and 1 hour post-ischemia in the infarcted left ventricles 
compared with that of sham group (P <0.05), then increased as reperfusion time extended 
to 4 hour (not significant vs. sham group) and reached the maximum level at 24 and 48 
hour after MI/R (P <0.05 vs. sham control group). CSE mRNA PCR product in the 
ischemic left ventricle declined thereafter at 72 hour (p=0.08, not significant, for 72 h 






































Figure 3.4. The time course of CSE mRNA expression following MI /R.  
A significant decrease of CSE mRNA is observed in myocardial ischemia regions at the 
end of ischemia and at 1 h reperfusion, while the CSE mRNA expression increased at 24 
h and 48 h and declined at 72 h after I /R thereafter.  
Data are given as means ± S.E.(n= 4- 6). 
 a P<0.05 compared to sham group 
 
 
Hours after initiation of MI/R 
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3.2.2   H2S production in the ischemic left ventricle 
 
Figure 3.5 displays the H2S production (CSE catalyzing activity) in the ischemic left 
ventricle subjected to MI/R and sham control group at different reperfusion points (n=4-6 
for each point). We found that the trend of H2S production almost followed the pattern of 
the CSE mRNA expression in the left ventricle: the CSE catalyzing activity decreased at 
1 hour after induction of reperfusion (P<0.05 versus sham control group), increased 
consistently at 4 hour after MI/R ( N.S. vs. sham control group), thereafter peaked at 24-
48 hour (P <0.01 versus sham control group), then correspondingly declined at 72 hour 











































Figure 3.5. The time course of H2S formation following MI/R.  
A significant decrease of H2S production in myocardial ischemia regions at 1 h 
reperfusion. H2S production increased at 24, 48 and 72 hour reperfusion.  
Values are means ± S.E.(n= 4-6).  
a P<0.05 compared to sham group, b P <0.01 compared to sham group 
 
Hours after initiation of MI/R 
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3.2.3   Effects of PAG on H2S production 
 
Because H2S production reached the maximum level at 24 hr reperfusion, we choose 
the 24 hr as the time point to evaluate the inhibition by PAG. The H2S production (Figure 
3.6) in the ischemic left ventricle from vehicle-treated group increased significantly after 
MI/R when compared with sham-operated controls (P < 0.05). Administration of the 
inhibitor PAG, as expected, dose-dependently decreased the H2S production (both 20 and 








































Figure 3.6. H2S production in ischemic left ventricular homogenate in rats treated 
with vehicle and different doses of PAG.  
Rats were subjected to 25 min of coronary artery occlusion followed by 24 h of 
reperfusion.   
Values are means ± S.E. (n= 4-6). 
 a P<0.05 compared to vehicle group. 
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3.2.4   Effects of PAG and NaHS on infarct size 
 
There were no significant differences in body weight (BW), heart weight (HW), 
HW/BW, left ventricle weight (LVW) and LVW/BW among all groups (data not 
provided). Infarct size (Figure 3.7) was expressed as percentage of the area at risk (AAR). 
for the vehicle group(n=10), the infarct size was 52.3%± 3.0%. 7.5 mg/kg PAG did not 
alter the infarct size(46.3%± 3.3 %, N.S.),  while the infarct size for 20 and 40 mg/kg 
PAG groups was 41.1%± 2.8% (P < 0.05 vs. vehicle group) and 39.3%± 2.9% (P < 0.01 
vs. vehicle group) of the AAR respectively. Compared to vehicle group, treatment with 







































Figure 3.7. Effects of PAG and NaHS on myocardial infarct sizes in rats treated 
with vehicle, PAG and NaHS..  
Rats were subjected to 25min of coronary artery occlusion followed by 48 h reperfusion.  
Open circles represent individual rat; solid circles are means ± S.E..  
a P<0.05 compared to vehicle-treated group, b P <0.01 compared to vehicle-treated group.  
 
VEH           PAG7.5           PAG20          PAG40           NaHS 
n=10              n=7                n=8               n=8                n=8 
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3.2.5   Effects of PAG and NaHS on left ventricular function 
 
Figure 3.8.-3.10. depict the left ventricular mechanic function parameters at 4h, 24h 
and 48 h after MI/R including LVDevP, LV + dP/dt max and LV - dP/dt max. Compared 
with sham group, significant decreases in LVDevP, LV + dP/dt max, LV - dP/d tmax 
were noted in animals subjected to MI/R( P <0.05). Figure 3.8. depicts that 40mg/kg 
PAG improved significantly LVDevP at 4h, 24h and 48 h after MI/R compared to vehicle 
group (P <0.05) while 7.5 mg/kg and 20 mg/kg PAG had no such effects at any 
reperfusion time point (P <0.05 vs. sham group). NaSH did not alter LVDevP at 4h, 24h 
































Figure 3.8. Changes in LVDevP (mmHg) in rats treated with vehicle, PAG and 
NaHS.  
Rats were subjected to 25min of coronary artery occlusion followed by 4, 24 and 48 h 
reperfusion.  
Values are means ± S.E. (n= 6-9)  




40 mg/kg PAG (Figure 3.9. and  3.10.) improved significantly LV+dP/dt max and LV 
-dP/dt max at 24h and 48 h, but not at 4 hour after MI/R compared to vehicle (P <0.01 
and 0.05 respectively), 7.5 mg/kg and 20 mg/kg PAG improved significantly LV+dP/dt 
max only 48 h after MI/R (P <0.05 vs. vehicle group), but did not alter LV -dP/dt max at 
any time point (P >0.05 vs. vehicle group). NaHS did not alter LV+dP/dt max and LV -
dP/dt max at 4h, 24h and 48 h after MI/R   (N.S.) compared with vehicle group. 
Preliminary experiments were carried out to determine the effect of PAG(40 mg/kg, 
i.p.) and NaHS (pump implant) on the mean arterial pressure (MAP), heart rate(HR) and 
LV haemodynamics of control(non MI/R) animals. Treatment with either drug failed to 
affect MAP, HR and LV haemodynamics (data not provided).  
In this experimental, post-treatment of 40 mg/kg PAG and NaHS (pump implant) did 
not affect mean arterial pressure (MAP) and heart rate(HR) compared to vehicle (data not 
provided).  
Put together, PAG restored the left ventricular function in a dose-dependent manner 
and the higher dose, 40 mg/kg, of PAG increased the LVDevP, LV + dP/dt max and LV - 
dP/dt max at 24 and 48 hour, but also increased the LVDevP at 4 hour after initiation of 
reperfusion. However, NaHS had no effect on the LVDevP, LV + dP/dt max and LV - 








































Figure 3.9. Changes in LV +dP/dt max in rats treated with vehicle, PAG and NaHS.   
Rats were subjected to 25 min of coronary artery occlusion followed by 4, 24 and 48 h 
reperfusion.  
Values are means ± S.E. (n= 6-9)  














































Figure 3.10. Changes in LV - dP/dt max in rats treated with vehicle, PAG and NaHS.   
Rats were subjected to 25 min of coronary artery occlusion followed by 4, 24 and 48 h 
reperfusion.  
Values are means ± S.E. (n= 6-9).  
a P<0.05 compared to vehicle group, b P <0.01 compared to vehicle treated group. 
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3.2.6   Effects of PAG and NaHS on MPO activity 
 
Treatment with PAG significantly decreased the MPO activity (Figure 3.11) at 4 h 
and 24 h after MI/R compared to their respective vehicle-treated groups ( both P <0.05). 
















































Figure 3.11. MPO activity in ischemic left ventricle in rats treated with vehicle, PAG 
and NaHS.   
Rats were subjected to 25 min of coronary artery occlusion followed by 4 and 24 h 
reperfusion.  
Values are means ± S.E. (n= 4 – 6).   












3.2.7   Effects of PAG and NaHS on cytokine levels 
 
Figure 3.12. shows protein levels of pro-inflammatory cytokines (TNF-alpha, IL-
1beta and IL-6) in ischemic left ventricle at 4 hour after MI/R. In vehicle-treated controls, 
reperfusion significantly increased protein levels of all three cytokines in the ischemic 
myocardium at 4 hour after MI/R, but none of the three cytokine expressions in the 
vehicle-treated group at 4 hour after MI/R differed from that of sham-operated animals. 
In PAG-treated animals, expressions of IL-1beta, IL-6 and TNF-alpha were significantly 
lower (P < 0.05 vs. vehicle). NaSH had no such effect on the three cytokines at 4 hour 
after MI/R (P >0.05 vs. vehicle). At 24 hour after MI/R, none of the three cytokine 
expressions in the vehicle- , PAG- and NaHS- treated group compared with sham group 

























































































Figure 3.12. Myocardial cytokine level in ischemic left ventricle in rats treated with 
vehicle, PAG and NaHS.   
Rats were subjected to 25 min of coronary artery occlusion followed by 4 h reperfusion.  
Values are means ± S.E. (n= 4-6) 
a P<0.05 compared to vehicle-treated group. 
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3.3    Results of Experiment 3: NO-Paracetamol Reduces Pro-
inflammatory Hydrogen Sulfide in Myocardial Ischemia Reperfused 
Rat 
3.3.1.  Effects of paracetamol and NO-Paracetamol on systemic BP and HR 
 
5-8 rats treated with vehicle, paracetamol, NO-Paracetamol and SNP were randomly 
selected for the measurement of systemic blood pressure (systemic BP) and heart rate 
(HR) at 2 time points: just prior to drug treatment (baseline); and at 2 h after the last drug 
treatment on day 3. Baseline BP and HR values were in the same range in all treatment 
groups. After 3-day treatment, neither NO-Pareacetamol nor pareacetamol significantly 
altered MAP or HR compared to their baseline level (Figure 3.13 and 3.14). However, 
SNP significantly decreased systemic blood pressure (P < 0.05 compared to baseline), but 
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Figure 3.13. Effects of pre-treatment with vehicle, PARA, NOP and SNP on systemic 
BP.  
Measurements were on day 1 (prior to pre-treatment, baseline), day 3 (after 3 consecutive 
days of treatment). BP, blood pressure; PARA, paracetamol (16mg/kg, i.p.); NOP, NO-
Paracetamol (30 mg/kg, i.p.); SNP, sodium nitroprusside (31.7 mg/kg, pump implant).   
Results are mean ± S.E.(n=5-8). 
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Figure 3.14. Effects of pre-treatment with vehicle, PARA, NOP and SNP on HR.  
Measurements were on day 1 (prior to pre-treatment, baseline), day 3 (after 3 consecutive 
days of treatment).  HR, heart rate (beats per minute); PARA, paracetamol; NOP, NO-
Paracetamol; SNP, sodium nitroprusside.  
Results are mean ± S.E. (n=5-8). 




3.3.2   Effects of paracetamol and NO-Paracetamol on infarct size  
 
There were no significant differences in body weight (BW), heart weight (HW), 
HW/BW, left ventricle weight (LVW) and LVW/BW among all groups (data not 
provided). Infarct size (Figure 3.15) was expressed as percentage of the area at risk 
(AAR).  For the vehicle group (n=9), infarct size was 53.2%± 2.9 %.  Paracetamol 
treatment did not alter the infarct size(46.3%± 3.3 %, N.S.);  while the infarct size for 10 
and 30 mg/kg NO-Paracetamol groups was 42.1%± 3.0% and 38.3%± 3.4% (both P < 
0.05 when compared to the vehicle group). There was a significant difference observed 
between paracetamol and 30 mg/kg NO-Paracetamol-treated groups (P<0.05). Compared 
to vehicle group, treatment of SNP also decreased infarct size (P<0.05) but there was no 
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Figure 3.15. Infarct size as percentage of the area at risk in rats treated with vehicle, 
PARA, NOP and SNP.   
Rats were subjected to 25 min of coronary artery occlusion followed by 24 h reperfusion. 
PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium nitroprusside.  
Values are means ± S.E.  
a P < 0.05 vs. vehicle treated group. b P < 0.05  vs. paracetamol(PARA) treated group.  
 
 
VEH            PARA             NOP10         NOP30             SNP  
n=9               n=8                 n=8               n=8                 n=8 
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There were no significant differences in body weight (BW), heart weight (HW), 
LV/BW( data not provided) and the percentage of area at risk(AAR) of LV(AAR/LV, P 
>0.05 vs. vehicle-post-treated animals) in groups post-treated with NO-Paracetamol and 
SNP. Post-treatment of 30 mg/kg NO-Paracetamol and SNP failed to alter infarct size 






























Figure 3.16. Infarct size as percentage of left ventricle (LV) and the area at risk 
(AAR) in rats post-treated with vehicle, NOP and SNP. VEH, vehicle; NOP,  
NO-Paracetamol (30 mg/kg, i.p.); SNP, sodium nitroprusside (31.7 mg/kg, pump 
implant). Rats were subjected to 25 min of coronary artery occlusion followed by 24 h of 
reperfusion.  
Values are means ± SE(n= 6-8).  
No significant differences (P >0.05) were noted. 
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3.3.3   Effects of paracetamol and NO-Paracetamol on left ventricular function  
 
Figure 3.17 – 3.19 depict the left ventricular mechanic function parameters at 4h and 
24h after MI/R including LVDevP, LV + dP/dt max and LV - dP/dt max.  Figure 3.17 
shows that paracetamol did not change the left ventricular function; however, pre-
treatment with 30mg/kg NO-Paracetamol and SNP improved LVDevP at 4h and 24h after 
MI/R significantly when compared to vehicle group (P <0.05). Meanwhile, compared 
with the paracetamol-treated group, 30mg/kg NO-Paracetamol improved LVDevP at 24h 
after MI/R significantly (P < 0.05). 
30mg/kg NO-Paracetamol and  SNP improved LV+ dP/dt max (Figure 3.18 ) and 
LV- dP/dt max (Figure 3.19) at 4h and 24h after MI/R significantly compared to vehicle 
group (P <0.05). Compared with paracetamol-treated group,  30mg/kg NO-Paracetamol 





































Figure 3.17. Changes in LVDevP(mmHg)  in rats treated with vehicle, PARA, NOP 
and SNP.  
Rats were subjected to 25 min of coronary artery occlusion followed by 4 h and 24 h 
reperfusion. VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium 
nitroprusside.  
Values are means ± S.E. (n= 5-8)  


































Figure 3.18. Changes in LV + dP/dt max in rats treated with vehicle, PARA, NOP 
and SNP.  
Rats were subjected to 25 min of coronary artery occlusion followed by 4 h and 24 h 
reperfusion. VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium 
nitroprusside.  
Values are means ± S.E.(n= 5-8).  





























Figure 3.19. Changes in LV - dP/dt max in rats treated with vehicle, PARA, NOP 
and SNP.  
Rats were subjected to 25 min of coronary artery occlusion followed by 4 h and 24 h 
reperfusion. VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium 
nitroprusside.  
Values are means ± S.E. (n= 5-8)  





3.3.4   Effects of paracetamol and NO-Paracetamol on ischemic left ventricular H2S 
production 
 
A 3- day pre-treatment with paracetamol (PARA), NOP(NO-Paracetamol) and SNP,  







































Figure 3.20. H2S production in ischemic myocardial homogenate in rats after 3-day 
pre-treatment with vehicle, PARA, NOP and SNP.  
VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium nitroprusside.  
Values are means ± S.E. (n= 4-6). 
No significant differences were noted. 
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The formation of H2S by ischemic left ventricular homogenates from rats subjected to 
24 hour MI/R was significantly greater (vehicle group, P < 0.05) than in homogenates 
prepared from sham-operated rats (Figure 3.21) and higher than those in the homogenates 
before MI/R (5.0 vs. 3.4 nmol/mg soluble protein, Figure 3.20 and 3.21). Treatment of 
paracetamol did not affect the resulting rise in formation of significant amounts of H2S in 
the ischemic left ventricle at 24 hr reperfusion (Figure 3.21). In contrast, NO-Paracetamol 
pre-treatment resulted in a significant inhibition of MI/R-induced increase in the H2S 
formation in the ischemic left ventricle compared with vehicle- and paracetamol- pre-









































Figure 3.21. H2S formation in ischemic left ventricular homogenate in rats pre-
treated with vehicle, PARA, NOP and SNP.  
Rats were subjected to 25 min of coronary artery occlusion followed by 24 h reperfusion. 
VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium nitroprusside.  
Values are means ± S.E. (n= 4-6) 
a P <0.05 compared to vehicle group, b P <0.05  compared to paracetamol (PARA) 
treated group. 
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3.3.5   Effects of paracetamol and NO-Paracetamol on myocardial 
MPO activity 
 
Pre-treatment of paracetamol did not affect the resulting rise in the increase of MPO 
activity in the ischemic left ventricle (Figure 3.22). In contrast, NO-Paracetamol pre-
treatment resulted in a significant inhibition of MI/R-induced increase in the MPO 
activity in the ischemic left ventricle compared with vehicle- and paracetamol- pre-









































Figure 3.22. MPO activity in ischemic left ventricle in rats pre-treated with vehicle, 
PARA, NOP and SNP.  
Rats were subjected to 25 min of coronary artery occlusion followed by 24 h reperfusion. 
VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium nitroprusside.  
Values are means ± S.E. (n= 4-6). 




3.3.6   Effects of paracetamol and NO-Paracetamol on myocardial cytokine levels 
 
Figure 3.23 shows the protein levels of pro-inflammatory cytokines (TNF-alpha, IL-
1beta and IL-6) in ischemic left ventricle at 4 hours after MI/R. In vehicle-treated 
controls, reperfusion significantly increased protein levels of the three cytokines in the 
ischemic myocardium. Treatment of paracetamol did not affect the rise in the increase of 
cytokine levels. In contrast, in NO-Paracetamol and SNP-treated animals, expression 
levels of IL-1beta, IL-6 and TNFalpha were significantly lower (P < 0.05).  Moreover, 
NO-Paracetamol decreased the cytokine expression compared to pareacetamol-treated 
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Figure 3.23. Myocardial cytokine levels in ischemic left ventricle in rats pre-treated 
with vehicle, PARA, NOP and SNP.  
Rats were subjected to 25 min of coronary artery occlusion followed by 4 h reperfusion. 
VEH, vehicle; PARA, paracetamol; NOP, NO-Paracetamol; SNP, sodium nitroprusside.  
Values are means ± S.E.(n= 4-6). 




Summary of the findings of the three experiments: 
 
In the first experiment, we found that pre-treatment of NOA significantly restored 
ischemia/reperfusion-induced myocardial contractile dysfunction, decreased infarct size 
and downregulated the iNOS mRNA expression and plasma NOx concentration 
compared with those of vehicle or aspirin-treated groups. These beneficial effects of 
NOA probably derive mainly from the NO moiety, which interferes with and modulates 
the iNOS-induced cellular damage. However, pre-treatment with NOS inhibitor, L-
NAME, aggravated myocardial damage in terms of mortality and infarct size. The data 
showed that sufficient NO availability during ischemia reperfusion could confer the 
cardioprotection.  
 
In the second experiment, we examined the time course of CSE (H2S producing 
enzyme in heart) mRNA expression and activity during the MI/R. The biphasic pattern of 
H2S production was observed: declined in the early reperfusion, but increased hours after 
I/R and reached the maximal around 24-48 hour. Furthermore, the role of H2S in the 
reperfusion-characterizing inflammation was studied by applying a CSE inhibitor (PAG) 
and H2S donor (NaHS). The pro-inflammatory effect of H2S was noted by NaHS-induced 
neutrophil infiltration, and PAG-offered cardioprotection via inhibiting H2S biosynthesis, 
then attenuating pro-inflammatory cytokine-induced neutrophil infiltration. 
 
In the third experiment, we found that pre-treatment, but not post-treatment, with NO-
paracetamol exerted the cardioprotective effects, which is likely pre-treated-NO mediated 
the attenuatation of myocardial H2S production, pro-inflammatory cytokine levels and 
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MPO activation. Sodium nitroprusside (SNP), as a NO donor control, exerted the similar 
effects on the pro-inflammatory H2S production and neutrophil infiltration, however, 




















CHAPTER 4    DISCUSSION 
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4.1.   Discussion of results of Experiment 1 
 
The results of Experimental 1clearly demonstrated that the daily oral administration 
of NOA for 7 days before myocardial ischemia could offer noticeable cardioprotection by 
significantly limiting infarct size/lowering mortality rate caused by 25 min LCA 
occlusion followed by 48 h reperfusion: this confirmed previous finding infarct-limiting 
effect during early reperfusion (Burke et al., 2006; Rossoni et al., 2001; Wainwright et 
al., 2002); moreover, NOA-improved cardiac dysfunctional recovery was noted at 48 
hour of reperfusion.  
 
4.1.1.  Cardioprotection of pre-treatment with NOA  
 
In the present study, compared with equimolar dose of aspirin-treated animals, NOA 
displayed marked infarct-limiting effect. The mechanism(s) involved probably is that 
enhanced NO bioavailability initiates an ischemia preconditioning (IPC)-like 
phenomenon. Based on previous studies reported, exogenous NO (NO donor) could 
trigger/mediate cardiac adaptive protection against reperfusion injury from first 2-3 h to a 
few days (Nakano et al., 2000; Qin et al., 2004; Takano et al., 1998), although the exact 
targets or effectors of NO in IPC are open to investigation (Jones et al., 2006). Given the 
multifarious nature of NO’s chemical and physiological actions, NO could also exert 
inhibit platelet aggregation and neutrophil adhesion during reperfusion (Radomski et al., 
1990; Rossoni et al., 2001; Rubbo et al., 1994). We believe that the enhanced NO 
bioavailability by NOA pre-treatment elicited salubrious effects. Of note, NOA was not 
sufficient to cause any appreciable systemic BP and heart rate change compared to 
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baseline level, which might be due to the NO slow-releasing property; therefore, any 
difference in NOA treated group cannot be attributed to haemodynamic alterations. 
Pre-treatment with L-NAME before ischemia increased systemic BP compared to 
baseline level, and exacerbated the extent of myocardial reperfusion injury compared to 
vehicle group. But co-administration of NOA attenuated the hypertensive state and 
infarct size/mortality rate induced by L-NAME, these findings also agree with previous 
studies (Muscara et al., 2001; Rossoni et al., 2001). The mechanism is likely that 
exogenous NO supplement, by NOA in our study, constituted the reduced endogenous 
NO production by L-NAME inhibition before MI/R. In the normal physiological 
condition, endothelial NO synthase (eNOS) displayed more infarct-limiting effect than 
neuronal NO synthase (nNOS) did by comparing the infarct size among the wild-type, 
eNOS and nNOS knockout mice subjected to global MI/R (Sumeray et al., 2000). Jones 
et al. (Jones et al., 1999) also demonstrated that endothelial cell-derived NO played a 
vital role in vascular homeostasis within the coronary circulation and displayed the 
intrinsic defenses against MI/R-induced cardiomyocyte injury in eNOS  knockout mice. 
The beneficial effects of eNOS was supported by applying transgenic (TG) mice that 
overexpress eNOS exclusively in cardiac myocytes, these authors reported that high 
levels of NO/cGMP strongly protected against ischemia/reperfusion injury than wild-type 
mice (Sumeray et al., 2000). NOA, unlike conventional NO donors, releases NO 
intracellularly at a rate similar to that generated by endogenous eNOS (Fulton et al., 2004; 
Ignarro et al., 2002; Keeble et al., 2001). Thus, we propose that NO donated by NOA 
maintains or augments eNOS-exerting vasodilatory tone and defensive functions against 
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reperfusion injury, and abolishes the endothelial dysfunction and injury exacerbation by 
L-NAME when combined with NOA.  
4.1.2.  Cytotoxicity of iNOS-derived NO exacerbates LV dysfunction  
 
Our preliminary study (data not shown) showed that rats treated with NOA daily for 
two weeks (one week before acute myocardial infarction (AMI) and one week treatment 
continued after AMI(the same dosage as this study) displayed some, but not significant, 
cardioprotection compared to control group, the beneficial effects as evidenced by 
decreased infarct size/mortality to some extent. However NOA appeared to exacerbate 
cardiac dysfunction: a significantly higher hypertrophy index occurred than control group 
(P < 0.05). We hypothesized that this is likely due to NO accumulation during the 
myocardial infarction because of excessive NO released from the NO moiety plus large 
amount of NO induced from endogenous iNOS, where high concentration of NO  is 
believed to be detrimental to cardiac tissue (Cui et al., 1998; Takimoto et al., 2000; 
Wildhirt et al., 1997). Interestingly, Liang et al. (2004) demonstrated that L-Arginine 
(substrate for NO production) administered at different time points during 
ischemia/reperfusion exerted different effects on post-ischemic myocardial injury. 
 It is reported (Rossoni et al., 2001) that NOA did not change the cardiac mechanic 
parameters (LVP, LVDevP, heart rate) in rats subjected to 2 h reperfusion following 
myocardial ischemia. However our present study demonstrates NOA recovered LV 
function partially at 48 h after reperfusion, but the decrease of infarct size in NOA-treated 
groups was observed in all the three studies.  Moreover, it is interesting in the present 
study that plasma total NOx measured at 48 h reperfusion was significantly lower when 
treated with NOA compared to that of vehicle-treated animals in spite of  7-day NO 
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supplement. We speculate that iNOS-derived NO plays a vital role in NO accumulation 
during 2 days reperfusion and also results in the discrepancy of LV function among the 
three studies.  
Different from constitutive NOS (eNOS and nNOS), iNOS can be induced by pro-
inflammatory substances such as cytokines and lipopolysaccharide (LPS) or pathological 
conditions such as stroke, trauma, infection and a variety of cardiovascular diseases 
(Haywood et al., 1996) and produces higher levels of NO than the normal for a longer 
period (Paulus, 2001); Wildhirt et al. (1997 and 1999) reported that iNOS activity 
increased and reached maximal level range from 48-72 h after initiation of  AMI  and 
MI/R in rabbits, which was also supported by significant increases in plasma NOx level 
and cardiac iNOS mRNA expression in control group compared to sham group. Although 
considerable evidence exists that NO itself has low reactivity with most biological 
molecules and is cytoprotective, large amounts of NO produced by iNOS are recognized 
as a mediator and regulator of inflammatory responses (Schulz et al., 2004; Zweier et al., 
1995). Because overproduction of NO can combine with superoxide to form the potent 
oxidant peroxynitrite (ONOO-), a highly cytotoxic molecule that contributes to cardiac 
dysfunction and myocardial injury in MI/R (Ferdinandy et al., 2003; Ronson et al., 1999); 
inhibition of iNOS could cause the recovery of the LV function and protect the salvaged 
reperfused myocardium against post-infarction dysfunction (Wildhirt et al., 1997; 
Wildhirt et al., 1999). 
Therefore, the timing of exogenous NO supplement, the enzymatic source of 
endogenous NO generation in physiological / pathological conditions and the concurrent 
formation of the toxic reaction product between NO and reactive oxygen species (ROS) 
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could explain the discrepancy between the present and the preliminary study on cardiac 
mechanic dysfunction. Of note, whether NO released from NOA interacted with the 
endogenous NOS before and during the MI/R needs further investigation, which is 
beyond the scope of the present study. 
 
4.1.3.  Pre-treatment with  NOA on COX  mRNA expression  
 
Another point of interest is to evaluate mRNA level of COX isoforms mRNA level at 
48 hour reperfusion. The two distinct COX isoforms, namely COX-1 and COX-2, have 
been charactered. COX-1 is constitutively expressed in most cells, mostly in platelets and 
endothelial cells and is responsible for homeostatic prostanoid formation, and COX-2, 
which is almost undetectable or lower in basal conditions, is dramatically upregulated in 
response to stress, such as inflammatory cytokines and ischemia, and often involves 
harmful effects including trauma, LPS-induced inflammation and I/R injury. Several 
reports have suggested that the inhibition of COX-2 ameliorates damage to tissues ( lung, 
kidney and liver) triggered by  I/R injury (Feitoza et al., 2005; Ito et al., 2003; Zamora et 
al., 1993). and inhibition of COX-2 significantly improved cardiac function in dogs 
following transplantation (Oshima et al., 2006). Moreover,  COX-2 inhibitors protected 
the endothelial function against the deleterious effect of ischemia and reperfusion in 
isolated rat hearts (Bouchard et al., 1999). Therefore, we deduced that pre-treatment with 
NOA may attenuate COX-2 expression, and in turn, ameliorate cardiac malfunction and 
damage in this study.  
Another reason to investigate COX-2 mRNA expression is that COX-2 is closely 
related with iNOS. First, COX-2 is found to be co-induced together with iNOS in cardiac 
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myocytes and many other cell types during inflammation and ischemia (Mendez et al., 
2003; Ohama et al., 2007; Vane et al., 1994). Furthermore, the signaling molecules that 
induce the expression of COX-2 in response to stress are similar to those that activate 
iNOS expression, including nuclear factor-kappa B (NF-κB) (Chiang et al., 2005; 
Schmedtje et al., 1997) and protein kinase C (PKC) (Banan et al., 2002; Molina-Holgado 
et al., 2000).  The COX-2 mRNA expression results validate our hypothesis: NOA 
caused a significant decrease of COX-2 mRNA expression, similar to the decrease of 
iNOS mRNA compared to vehicle (P < 0.01). It may be concluded from this study that 
pre-treatment with NOA attenuated MI/R injury possibly by blunting COX-2 induction 
during reperfusion. 
nNOS, eNOS and COX-1 are constitutively expressed gene and the change of three 
genes were not noted in the MI/R in the vehicle groups. We also did not observe the 
influence of pre-treatment of ASA, NOA and L-NAME on their mRNA expression, 
which demonstrated that only iNOS and COX-2 played the roles of reperfusion injury at 
48 hr reperfusion. 
 
In summary of Experimental 1, NOA exerts a better cardioprotective effect than 
aspirin in the rat model of ischemia and 48 h reperfusion. It attenuated myocardial injury 
by limiting infarct size and allowing left ventricular function recovery following ischemia 
and reperfusion. Thus, the beneficial effect of NOA in decreasing iNOS and plasma NOx 
levels seems to involve a NOS-dependent pathway. It also needs to be explored whether 
other mechanisms or molecular targets of NO are involved in the protection of 
postischemic injury. The findings of this study, however, offer a new possibility for NOA 
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pre-treatment in management of reperfusion injury. The cardioprotective effect of NOA 
would also benefit the aged and endothelial-function impaired patients for whom 
myocardial dysfunction is a common life-threatening complication. 
 120
4.2    Discussion of results of Experiment 2 
 
The Experimental 2 investigated the time course of CSE mRNA and its catalyzing 
activity in the rat heart after ischemia-reperfusion. The high output CSE/ H2S pathway is 
activated, contributing to left ventricular dysfunction and extent of infarct size. Moreover, 
the deleterious effects mediated by CSE activation are reversed by selective inhibitor 
(PAG), leading to a significant reduction of infarct size, an important determinant of 
survival after myocardial injury, and the recovery of left ventricular function. The data 
presented here suggest that H2S may play a role in the inflammation caused by 
reperfusion injury via activating pro-inflammatory cytokine-induced neutrophil 
infiltration. 
4.2.1   H2S production in the MI/R 
 
Results of the time course of H2S formation showed that cardiac CSE mRNA 
expression and CSE catalyzing activity changed in a biphasic manner during reperfusion 
following a 25 min period of ischemia. Compared to sham group,  H2S production 
decreased at 1 h after initiation of reperfusion. This could be explained by the ischemia 
insult: in the acute myocardial infarction (AMI) model, It is  also observed (Zhu et al., 
2007) that CSE gene expression and H2S biosynthesis activity in myocardial ischemic 
zone, as well as plasma H2S concentration, were significantly reduced compared to those 
of sham group after AMI. In another isoproterenol-induced myocardial injury study, 
Myocardial CSE activity was also reduced (Geng et al., 2004a). The molecular 
mechanism for CSE downregulation during ischemia is not clear now. One possible 
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explanation is that heart is adaptive to stress condition, such as ischemia or low 
blood/oxygen supply. 
When the reperfusion time extended, increased CSE expression and activity were 
observed from 4 hours following reperfusion (P > 0.05 vs. sham control), and reached the 
maximum level between 24 and 48 hour following reperfusion. The second phase of 
increased H2S production may be due to NO, which is known to play an important role in 
the inflammation induced by MI/R. The synthetic pathway for H2S production was 
interfered with the synthetic pathway for NO, and NO could influence the expression and 
activity of CSE by impairing the reduced glutathione/oxidized glutathione balance and/or 
by inhibiting enzymes and ion channels through S-nitrosylation processes. For example, 
Zhong et al reported that L-NAME inhibited CSE gene expression and CSE activity  in 
thoracic aorta and superior mesenteric artery (Zhong et al., 2003). In addition, conversion 
of L-cysteine to H2S in rat aortic tissue is enhanced following sodium nitroprusside (SNP, 
a NO donor) treatment (Zhao et al., 2001). SNP also increased the expression of CSE in 
cultured vascular smooth muscle cells (Zhao et al., 2001). Interestingly, NO production 
(from iNOS) did start to be increased hours after initiation of reperfusion (Liu et al., 1997) 
and also reach the maximum level around 48 hour after MI/R (Wildhirt et al., 1999). 
Hence, it is rational to hypothesize that iNOS-induced NO contributes the increase of H2S 
production. However, it remains unproven, and further studies will be required to 
elucidate the precise mechanisms involved in the biphasic upregulation of CSE 
expression in the postischemic myocardium. 
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4.2.2   Is effect of H2S in the reperfusion injury cardioprotective or detrimental? 
 
Available reports indicated that H2S was a cardioprotective agent in the MI/R via 
KATP pathway (Bian et al., 2006; Johansen et al., 2006), or by preservation of 
mitochondrial function (Elrod et al., 2007), which is in agreement with our preliminary 
results (the relevant experiment on mitochondrial function is under way in our lab). 
However, our present study demonstrated post-treatment of PAG decreased the 
reperfusion injury and post-treatment with NaHS (via pump implant) did not show 
cardioprotective effect.  
One possible explanation for the discrepancy is the different treatment time of H2S 
donor/inhibitor. Pre-treatment (Johansen et al., 2006) or immediate post-treatment (Elrod 
et al., 2007) of  NaHS may exert ischemia precondition (IPC)-like effect (Bian et al., 
2006), just like NO donor which could confer cardioprotection via pre- or post-
conditioning in the heart (Jones et al., 2006; Vinten-Johansen et al., 2005). Whereas in 
our present study, at the critical time (first few hours after I/R), the amount of slow-
released NaHS from the pump was not sufficient to trigger the signaling survival pathway 
in the postconditioning as Elrod et al reported (Elrod et al., 2007). 
4.2.3   H2S is a pro-inflammatory mediator in the reperfusion injury 
 
The reperfusion injury is characterized by inflammatory responses involving the 
activation of pro-inflammatory cytokine and neutrophil infiltration (Taqueti et al., 2006). 
Our data showed that PAG decreased pro-inflammatory cytokine expression and MPO 
activity after I/R, but the administration NaHS (via pump implant) increased the MPO 
activity 24 hours after I/R; the H2S-induced neutrophil infiltration were also reported in 
other inflammation model (Bhatia et al., 2005b; Li et al., 2005; Zhang et al., 2007b).  
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Interestingly, NaHS did not affect the cytokine expression and neutrophil infiltration 
4 hours after I/R. There are two possible explanations: 1) the amount of released NaHS 
did not reach the concentration to influence the activation of cytokines at that time point; 
till accumulating for 24 hour after I/R, sufficient NaHS concentration exacerbated the 
neutrophil infiltration. 2)  some studies have demonstrated that low level of NaHS may 
be able to neutralize a variety of oxygen reactive radicals (Geng et al., 2004a) and 
peroxynitrite (Whiteman et al., 2004). Thus, exogenous H2S may act as an antioxidant in 
the first few hours when the endogenous H2S was deficient due to ischemic insult. From 
this point of view, we could conclude H2S exerted anti-inflammatory activity when 
administered upon the initiation of reperfusion, and caused the cardioprotective effect 
(Elrod et al., 2007). Nevertheless, as the reperfusion time extended, the augmented 
endogenously synthesized H2S, plus the exogenous H2S from NaHS, became an 
inflammation mediator. Thus, in our present study, pharmacological intervention (i.e. 
treatment with PAG) not only reduced tissue H2S formation but also exhibited marked 
anti-inflammatory effects.  
Our preliminary experiments demonstrated that PAG (40 mg/kg, i.p.) and NaHS 
(pump implant) failed to affect the mean arterial pressure (MAP), heart rate (HR) and LV 
haemodynamics of control (non MI/R) animals. The results were supported by other 
studies (Mok et al., 2004; Sivarajah et al., 2006). These findings ruled out the possibility 
that PAG and NaHS at current dosage altered the haemodynamic parameters during MI/R. 
Study Limitation  
PAG is accepted as an  irreversible CSE inhibitor (Marcotte et al., 1975) and has been 
used in several studies to test the biological effect of inhibition of endogenous H2S 
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production (Bhatia et al., 2005b; Nagai et al., 2004; Sivarajah et al., 2006; Zhang et al., 
2007b; Zhu et al., 2007). Whereas this compound is of low potency, of limited cell-
membrane permeability and nonspecifically interfering with other enzymes (Burnett et al., 
1980; Marcotte et al., 1976; Wang, 2002). Hence, in this study, the possibility can not be 
excluded that PAG exerted other CSE independent effects, which may be of benefit after 
I/R. Research on potent and specific CSE inhibitors, or cardiomyocyte-specific CSE 
knockout mice in MI/R model are required in the future.  
In summary, this is the first study which provides evidence that H2S production and 
administration of PAG following acute myocardial ischemia and reperfusion exerts 
protective effect with respect to myocardial performance, neutrophil infiltration and 
reduction of infarct size.  
Based on these findings, we suggest that H2S synthesis blockers may potentially be of 
clinical advantage under pathophysiologic conditions involved in I/R including 
myocardial infarction or coronary angioplastic procedures.  
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4.3    Discussion of results of Experiment 3 
 
This experimental 3 was carried out to investigate the cardioprotection of NO-
Paracetamol in a rat model of MI/R. Compared with equimolar dose of paracetamol, NO-
Paracetamol displayed significant dose-related cardioprotective effect as shown by the 
reduced infarct size and increased left ventricular function. NO-Paracetamol attenuated 
reperfusion-induced increase in myocardial H2S production, pro-inflammatory cytokine 
levels and neutrophil infiltration. Furthermore, the protective effect of NO-Paracetamol 
was lost 3 hours after the initiation of reperfusion. These findings suggest interesting 
information regarding the cardioprotective mechanism of NO-Paracetamol. 
 
Firstly, the present study confirmed our previous work (see Experimental 1) showing 
that the NO moiety of NO-Aspirin is responsible for its cardioprotective effect. Their 
respective parent compound (paracetamol or aspirin) had no or less effect on the 
parameters of reperfusion injury measured indicating that NO released following 
cleavage of NO-Paracetamol was the molecule responsible for the changes observed. 
Moreover, in the present study, classical NO donor, SNP, exerted an equivalent 
cardioprotection as reported by others (Du Toit et al., 2001; Garreffa et al., 2006; Masini 
et al., 1999), thus it may thereby be deduced that NO moiety was the active component.  
Of note, SNP, although administered via osmotic minipump in this study, was 
observed to result in a decrease in the systemic BP due to a rapid, but transient NO 
release (Eduardo da Silva-Santos et al., 1999). However, like NO-Aspirin, NO-
Paracetamol also did not  change blood pressure, probably due to the slow time course of 
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NO release, which confirmed the result by Marshall et al. (2006). Thus, the 
cardioprotective effect of NO-Paracetamol is not attributed to haemodynamic alteration. 
 
Secondly, NO-Paracetamol attenuated the H2S formation during MI/R. We have 
reported that myocardial reperfusion in the rat results in increased H2S production 
coupled with unregulated CSE mRNA expression in the ischemic myocardium (see 
Experiment 2). We have further shown that PAG, an inhibitor of CSE enzyme, attenuated 
the reperfusion injury as evidenced by the reduced infarct size, myocardial pro-
inflammatory cytokine level and neutrophil infiltration (see Experiment 2). Furthermore, 
H2S administration (by pump implanted NaHS, a H2S donor) resulted in augmented 
myocardial MPO activity (see Experiment 2). 
In the present experiment, we observed that pre-treatment with NO-Paracetamol and 
SNP, but not paracetamol, attenuated the myocardial H2S production, pro-inflammatory 
cytokine level and MPO activation. Interestingly, a similar H2S production- decreasing 
and anti-inflammatory effect of NO-NSAID( nitroflurbiprofen) has been reported in the 
LPS induced inflammation in the rat (Anuar et al., 2006). 
A possible explanation for the attenuation of myocardial H2S production, pro-
inflammatory cytokine level and MPO activation may be that NO triggered a 
preconditioning (PC)-like phenomenon (Ferdinandy et al., 2003) via S-nitrosylation or 
ion channel activation (Andoh et al., 2000; Lin et al., 2004; Sun et al., 2007). The 
molecular basis underlying this effect has not been elucidated. The present data suggest 
that CSE activity may be modulated by exogenous NO and is therefore of potential 
significance in a spectrum of pathogenesis involving over-synthesis of H2S (Tvedt et al., 
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1991; Du et al., 2003; Hui et al., 2003; Yan et al., 2004; Yang et al., 2004b; Bhatia et al., 
2005a; Yusuf et al., 2005;Yang et al., 2006; Qu et al., 2006;Zhang et al., 2007a).   
Another explanation for the attenuation of myocardial H2S production, pro-
inflammatory cytokine level and MPO activation is the interaction of iNOS-derived NO 
and H2S. H2S formation and physiological function are linked with NO. As discussed in 
Experiment 3, NO could influence the expression and activity of CSE by impairing the 
GSSH/GSH balance and/or by inhibiting enzymes and ion channels. Furthermore, a novel 
nitrosothiol generated by reacting H2S and NO may regulate the physiological effects of 
both NO and H2S (Whiteman et al., 2006). In addition, both H2S and NO may bind to 
haemoglobin, and then are quenched there (Searcy et al., 1998). 
We have reported (see Experiment 1) that the pre-treatment of NO-Aspirin (NOA) 
blocked the increase of iNOS mRNA expression, thus, there is a possibility that pre-
treatment with NO-Paracetamol caused the decrease of iNOS-derived NO, then 
subsequently the downregulation of H2S production and neutrophil infiltration.  
 
Thirdly, the finding that pre-treatment, but not post-treatment (3h after initiation of 
reperfuson) with NO-Paracetamol is cardioprotective against reperfusion injury gives us 
further information regarding the mechanism of NO. There is a significant inflammatory 
response induced in the first few hours after I/R, including the activation of monocytes, 
macrophages and neutrophils, release of pro-inflammatory cytokines and activation of 
complement (Frangogiannis et al., 2002; Kobayashi, 2006; Taqueti et al., 2006). 
Although NO released from NO-Paracetamol and SNP could exert an anti-inflammatory 
effect, e.g. inhibition of the synthesis of TNF-α, IL-6 and IL-1β (Marshall et al., 2004; 
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Minuz et al., 2001a; Minuz et al., 2001b), post-treatment with NO-Paracetamol 3 h after 
I/R may have failed to target  this critical stage in the reperfusion-induced inflammatory 
response and to reverse the pathogenesis of inflammation. 
 
From these findings of the three experiments, we believe that increased NO 
availability is a useful pharmacological intervention that limits tissue injury in MI/R (e.g. 
pre-treatment of NO-Aspirin, NO-Paracetamol and SNP in the Experiment 1 and 3). In 
contrast, insufficiency or loss of NO availability exacerbates reperfusion injury as L-
NAME did in the experiment 1. NO-NASIDs could be of better clinical significance due 
to the NO-slow-releasing property and do now influence the haemodynamics compared 
with conventional NO donor (e.g. SNP in the pump implant) in the Experiment 3. In 
addition, our results of experiment 2 showed that production of H2S increased as the 
reperfusion time extended up to 24-48 hour, just like NO in the MI/R (Wildhirt et al., 
1999), and H2S was likely to play a pro-inflammatory role in determining the severity of 
reperfusion injury in the rat model of MI/R. More importantly, we propose the 
appropriate dose of H2S inhibitor (PAG) could be of beneficial for the ischemia-
reperfused myocardium if administered at the initiation of reperfusion. Furthermore, the 
crosstalk between NO and H2S was found in the Experiment 3: pre-treatment of NO 
donors (NO-Paracetamol and SNP) attenuated the over-production of pro-inflammatory 
H2S. The new information regarding the roles of NO and H2S in myocardial ischemia-














CHAPTER 5     


























Here are the objectives of the thesis as stated in the introduction section: 
 
 
Objective 1: Whether supplement of NO to aspirin (by NOA) exert better 
cardioprotective effects than aspirin does in MI/R?   
 
Based on the results of the first experiment, we found that pre-treatment of NOA 
significantly offered the better cardioprotective effects by restoring ischemia/reperfusion-
induced myocardial contractile function and limiting infarct size compared with vehicle 
or aspirin-treated group. These beneficial effects of NOA probably derive mainly from 
the NO moiety, which modulates the iNOS-induced cellular damage. However, pre-
treatment with NOS inhibitor, L-NAME, aggravated myocardial damage in terms of 
mortality and infarct size. The data showed that sufficient NO availability before MI/R 
could confer the cardioprotection.  
 
Objective 2: The time course of H2S production during the MI/R? Is H2S a pro- or anti- 
inflammatory molecule in the inflammation induced by reperfusion? 
 
In the second experiment, we found the biphasic pattern of H2S production was 
observed: declined in the early reperfusion, but increased hours after I/R and reached the 
maximal around 24-48 hour. Furthermore, the role of H2S in the reperfusion-
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characterizing inflammation was studied by applying a CSE inhibitor (PAG) and H2S 
donor (NaHS). The pro-inflammatory effect of H2S was noted by NaHS-induced 
neutrophil infiltration, and PAG-offered cardioprotection via inhibiting H2S biosynthesis, 
then attenuating pro-inflammatory cytokine-induced neutrophil infiltration. 
 
Objective 3: NO-Paracetamol has the cardioprotective effects as a NO-slow-releasing 
donor? Is there any difference in the effects against the reperfusion injury 
between the pre-treatment and post-treatment of NO donor? Could NO-




According to the results of the third experiment, we found that pre-treatment, but 
post-treatment, with NO-paracetamol exerted the cardioprotective effects, which is likely 
pre-treated-NO mediated the decrease of myocardial H2S production, pro-inflammatory 
cytokine levels and neutrophil infiltration. 
 
 
NO is a pluripotent radical molecule and appear to play a very active role in MI/R 
(see Figure 5.1). Despite a lot of reports on the ability of NO donors to defend the 
myocardium against ischemia–reperfusion injury, some studies provide strong but 
somewhat conflicting evidence that NO is involved in the myocardial response leading to 
lethal injury upon reperfusion. The controversial results may be explained by the timing 
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It is gradually acknowledged that NO production has possible roles in reperfusion 
injury (see Figure 5.2). The cardiac interstitial NO (mainly from eNOS) concentration is 
within the nanomolar range during normoperfusion and negatively regulates the eNOS 
activity. During the prolonged ischemia, eNOS protein expression decreases (Giraldez et 
al., 1997; Wang et al., 1996), and the increased tissue acidosis attenuates eNOS activity 
(Giraldez et al., 1997). Nitric oxide bioavailability still appears to be reduced in the early 
period after reperfusion (Amrani et al., 1995). It is possible that the amounts of NO 
formed during late reperfusion are much higher than early because of great upregulation 
of iNOS, which requires over 4-6 h and is maximal at 48 h reperfusion (Wildhirt et al., 
1999). This delayed augmentation of NO level increases tissue injury, perhaps related to 
ONOO- generation. 
 
Not only does the great increase of iNOS-derived NO during late reperfusion 
contribute to reperfusion injury, but the NO deficiency in the early reperfusion is also an 
injury-causing factor. The cardioprotection of enhanced NO availability by administering 
NO donor, prior to, during or after ischemia, has been extensively reported (Bolli, 2001; 
Schulz et al., 2004). Using endothelial nitric oxide synthase (eNOS) knockout mice,  
Jones et al. (1999) found that infarct size was significantly augmented following 
ischemia reperfusion, but infarct size was significantly reduced in both lines of eNOS 











Figure 5.2. NOS and CSE activities following MI/R.  
 
(1), Experiment 1; (2), Experiment 2; (3), Experiment 3; (4), Ignarro et al, Nitric Oxide 
Biology and Pathobiology 2000. 
 
Constitutive NOS (mainly cNOS) and CSE continuously are activated at basal level. The 
resulting NO and H2S regulate their own production by negative feedback on cNOS and 
CSE. On the other hand, inducible NOS(iNOS) required de novo synthesis and so takes 
longer to increase in activity; the CSE mRNA and activity decreased at 25 minutes after 
initiation of ischemia and at 1 h upon reperfusion, but increased as the reperfusion 
extended noted in our present study. In early reperfusion (a few hours), the levels of NO 
and H2S fall in the postischemic tissue. It is likely that iNOS and CSE levels increase 
after the early reperfusion, releasing large amounts of NO and H2S. Both of these changes 
in NOS and CSE activity may contribute to the ischemia-reperfusion injury. In our study, 
pre-treatment with NO donors (NOA, NO-Paracetamol and SNP) and post-treatment with 
PAG (a CSE inhibitor) elicited cardioprotective effects evidenced by reduced infarct size, 
restoration of left ventricular function and attenuated myocardial neutrophil infiltration. 
Post-treatment of H2S donor, NaHS in implanted pump, exacerbated neutrophil 
infiltration 24 hours after I/R. 
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The underlying mechanisms involving NO against ischemia-reperfusion injury  
include anti-platelet aggregation, blockade of mitochondrial calcium uptake, inhibition of 
pro-inflammatory cytokine expression (Loscalzo et al., 2000). Bolli (2001) and Vinten-
Johansen et al. (2005) examined the role of NO as a trigger or mediator in the 
preconditioning/ or postconditioning. For example, exogenous NO  donor was 
demonstrated to be sufficient to induce an early IPC-like protection (Nakano et al., 2000; 
Qin et al., 2004). 
 
In our present study, we demonstrated that the biphasic manner of CSE/H2S 
production, similar to NOS/NO, in Experiment 2: a drop of CSE mRNA/ activity in the 
25 min  ischemia and early reperfusion, but an increase hours after I/R and the highest 
level around 24-48 h. Next, pre-treatment of NOA and NO-Paracetamol significantly 
restored reperfusion-induced myocardial contractile dysfunction, decreased infarct size 
(see Experiment 1 and 3) via modulation of iNOS and CSE expression/ or activity. 
However, pre-treatment with NOS inhibitor, L-NAME, aggravated myocardial damage in 
terms of mortality and infarct size (see Experiment 1). The data confirmed that sufficient 
NO availability during ischemia reperfusion could confer the cardioprotection. 
Furthermore, post-treatment with NO-paracetamol, 3 h after reperfusion, failed to exert 
the cardioprotective effects (see Experiment 3) which confirmed the importance of timing 
to augment NO availability. 
 
Some researchers reported that H2S was a cardioprotective agent in MI/R when H2S 
donors were administered, prior to ischemia (Johansen et al., 2006; Sivarajah et al., 2006) 
or immediately after reperfusion (Elrod et al., 2007), H2S may elicit preconditioning-like 
cardioprotection (Bian et al., 2006). In contrast, our present study demonstrated that post-
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treatment with PAG decreased the reperfusion injury while post-treatment with NaHS 
(slow releasing via pump implant) did not show cardioprotective effect ( see Experiment 
2).  
 
Another consideration for conflicting results is the amount of NO/or H2S produced in 
MI/R. 
 
Both NO and H2S could react with and neutralize a variety of oxygen free radicals 
(Ignarro, 2000; Loscalzo et al., 2000; Lowicka et al., 2007; Szabo, 2007).  Low levels of 
NO and H2S can exert additive effects with known antioxidant, including glutathione and 
superoxide dismutase. Inhibition of endogenous NO and H2S production has been shown 
to enhance the cytotoxic effect of exogenous NO ( see Experiment 1, L-NAME + NOA) 
and H2S (Yang et al., 2004), which suggests a cytoprotective  effect of low (physiological) 
levels of endogenous NO and H2S. In some disease states such as reperfusion injury (see 
experiment 1 and 2) and inflammation, higher NO and H2S exposure tends to be 
cytotoxic to the cells. We also observed that higher doses (500 µg/kg) of H2S donor 
(Na2S) did not alter infarct size as much as lower doses (10-100µg/kg) in mice (Elrod et 
al., 2007). 
 
Future research in reperfusion injury should focus more precisely on the absence of 
plasma or blood components in in vitro study, non-enzymatic NO/H2S production as a 
potential source of NO and species difference etc.  
 
These findings would support increased NO availability as a useful pharmacological 
intervention that limits tissue injury in MI/R. In addition, our results suggest that H2S is 
likely to play a pro-inflammatory role in determining the severity of reperfusion injury in 
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the rat model of MI/R. More importantly, we propose the appropriate dose of NO/H2S 
donor or inhibitor should be administered at appropriate time of myocardial ischemia 
reperfusion. 
 
Many questions remain to be answered: 
 
• How is H2S production upregulated in MI/R? 
• What are the upstream and downstream signaling molecules of H2S and which 
cell types are involved in MI/R? 
• How does the interaction between H2S and NO in MI/R occur in both  in vitro 
and in vivo systems?  
 
 
The use of mice with cardiomyocyte-specific overexpression or knockout of NOS/ 
CSE genes may further assist us to answer these questions. When these questions are 
explained and elucidated, a better understanding of the mechanisms related to NO/H2S in 
reperfusion injury will be helpful for developing successful therapy to attenuate the 
adverse consequences of acute coronary syndromes, coronary surgery and transplantation. 
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